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GENETICS OF OBESITY IN STARR COUNTY, TEXAS MEXICAN AMERICANS 
Heather Michelle Highland 
Advisory Professor: Craig L. Hanis, Ph.D. 
 Currently, over two-thirds of Americans are classified as over-weight or obese. 
Obesity increases risk for many other diseases including type 2 diabetes, heart disease, 
stroke, and cancer, making obesity the largest public health problem in America and 
most other Westernized nations. Hispanics have a higher rate of both obesity and type 2 
diabetes, making them a particularly interesting population in which to study obesity. 
For the last 33 years, the Starr County Health Studies has collected an array of 
phenotypes and biological samples from residents of Starr County, along Texas-Mexico 
border. This study includes 825 subjects who were not known to have diabetes at 
ascertainment. These subjects have now been seen a second time, on average 8.5 years 
later. At both visits we measured several aspects of obesity including BMI, 
bioimpedance to estimate percent body fat, and waist, hip, and arm circumferences. By 
using multivariate approaches to leverage the array of obesity measures, we have better 
captured both the amount of adipose tissue and the location of fat deposits.  
To assess association of obesity related traits with genetic variation from both 
genome-wide array data imputed to 1000 Genomes Phase 1 integrated dataset and 
exome sequencing, both gene-based and single variant tests were conducted. Through 
these single variant tests, we identified an association with waist to hip ratio and low 
frequency variants, in two adjacent GABA receptor subunit genes, GABRB2 and 
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GABRA6, including a nonsynonymous variant in GABRA6. Additional associations 
include an association with a composite measure of adiposity that encompasses degree 
of adiposity and location of excess fat above or below the waist and TREK1, a gene 
responsible for trafficking the GABAA receptor to the cell membrane. Gene based tests 
of rare variants yielded associations between central versus peripheral adiposity and 
ACSL1, a gene involved in triglyceride biosynthesis. Further replication is required to 
confirm these associations. While the importance of neuronal signaling pathways in 
body fat distribution has long been known, many aspects of these pathways are poorly 
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Chapter 1: Background and Significance 
Epidemiology and Impact of Obesity 
 With obesity prevalence increasing at alarming rates, it is now more important 
than ever to understand the risk factors and underlying biology of body fat mass and 
distribution. Obesity is defined as having a body mass index (BMI) of at least 30 
kg/m2(1).The prevalence of obesity has more than doubled between 1995 and 2012(1). 
Hispanics, particularly in Texas, consistently have a higher prevalence of obesity than 
the general United States population (Figure 1). The research presented here focuses on 
identifying genetic factors contributing to obesity specifically in the Mexican-American 
population of Starr County, Texas.  
	
Figure 1. Prevalence of obesity and overweight. The prevalence of BMI > 25kg/m2 in 
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 While one could argue whether obesity itself is a disease, it is certainly a risk 
factor for the development of many other diseases, including type 2 diabetes, heart 
disease, cancer, stroke, osteoarthritis, and sleep apnea. A decrease in body fat, lowers an 
individual’s risk of developing these comorbidities. These comorbidities contribute to 
the considerable economic impact of obesity in the forms of increased medical costs, lost 
productivity, and the diet and exercise industry. Individuals with elevated BMIs have 
higher costs for medical care; the biggest absolute increases are attributable to 
comorbidities of circulatory diseases (10.53% increase) including cardiovascular disease 
and myeloproliferative diseases (10.67% increase) such as chronic myelogenous 
leukemia and thrombocytosis in men and musculoskeletal conditions (3.46% increase) 
and circulatory diseases (4.27% increase) in women(2). Someone with a BMI of 45 will 
average more than double the medical costs of someone with a BMI of 19(2). In total the 
excess medical spending attributable to obesity was $147 billion in 2008(3). Beyond 
increased medical costs, employees with obesity are estimated to have a 22% increase in 
missed work over their normal-weight counterparts(4). While employers have increased 
costs due to obesity in the form of higher insurance premiums, lost labor, and decreased 
productivity, individuals have increased spending as well, largely in the form of medical 
expenditures and costs associated with attempts to lose weight. The weight loss industry 
accounts for more than $60 billion spending annually; this spending includes gym 
memberships, supplements, diet food, and weight loss plans(5).  
Lifestyle intervention, diet, exercise, and behavior therapy have all been shown 
to result in clinically significant weight loss in some people. In an 8-year behavioral 
intervention, 26.9% of individuals had a net weight loss of at least 10% at the end of the 
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study(6). This weight loss alters risk for comorbidities in a disproportionate manner; for 
example behavioral intervention aimed at reducing weight by 7%, also reduces risk of 
developing type 2 diabetes by 58%(7). The success of these studies is contrary to what 
was seen in early studies, where it was shown that nearly all weight was regained within 
5 years(8), leading to a common perception that achieving long-term weight loss is near 
impossible. However, population based studies of the NHANES 1999-2006 show that 
17.3% of individuals reported long term weight loss, defined as a >10% weight loss 
maintained for at least a year(9). In NHANES 1999-2002, 33.5% of overweight 
individuals that had lost at least 10% of their maximum weight experienced weight 
regain in the prior year(10).  
The National Weight Control Registry was designed to look at the behaviors of 
those that successfully maintained weight loss(11); this study found at 5 and 10 years of 
follow up that 86.6% of participants maintained at least 10% weight loss(12). Those that 
started with a bigger initial weight loss showed faster regain while those who had 
maintained weight loss for more than 2 years at baseline experienced less regain(12). 
Weight loss and maintenance, which leads to decreased risk of comorbidities, were once 
perceived to be near impossible. Now it is recognized that while difficult, a subset of the 
populations can achieve long-term weight loss through lifestyle changes. 
For those who cannot achieve sufficient weight loss through lifestyle changes, 
surgical interventions have become a viable option. Following weight-loss surgery, a 
majority of patients with diabetes, hypertension, hyperlipidemia, or obstructive sleep 
apnea had these comorbid condition(s) resolved(13, 14). Due to the overall impact on 
health, insurance companies now offer coverage for weight-loss surgeries such as gastric 
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bypass and gastric banding; however, changes in requirements, such as surgery center 
designation, may keep some from accessing this coverage(15). Different weight-loss 
surgeries have different risks and benefits. While gastric bypass (laparoscopic Roux-en-
Y gastric bypass) yields higher excess weight loss than the gastric band, 69% versus 
46%, gastric bypass comes with a higher risk of perioperative complications(16). The 
adjustable gastric band is subject to long-term complications that may result in a second 
operation due to band slippage, pouch dilation, or unsatisfactory weight loss(16). In 
2013 approximately 179,000 bariatric surgeries were performed in the United States(17). 
The rate has slowed considerably from the initial exponential growth seen in the early 
2000s(15). The decline in surgeries in 2011-2013 seen in Figure 2 may be due to 
different sources of data, but others have suggested the decline is due to combined 
economic recession and increased surgery center regulation(15, 18).
	
Figure 2. Incidence of Bariatric Surgery in the United States. Estimates from 1992-
2009 came from (18). Estimates from 2011-2014 came from (17). No estimates were 



















Obesity Risk Factors 
 The body accumulates fat as a means of storing energy when more calories are 
consumed than are expended. In his “thrifty gene” hypothesis, Neel proposed that 
evolutionarily, this stored energy allows someone to survive when food resources are 
scarce(19, 20). In developed societies, humans no longer have extended periods of food 
scarcity. Furthermore, the typical Western diet now consists of processed foods that are 
high in fat and sugar that are inexpensive and convenient. While diet is one part of the 
energy balance, energy expenditure must also be considered. As computers, television 
and video games have become ubiquitous across America, people are spending more 
leisure time in a sedentary state. This, coupled with an increase in desk jobs, has led to a 
significant decrease in total energy expenditure(19).  
Even though most members of Western society are exposed to this “obesogenic” 
environment, not everyone becomes obese(21). This difference may, in part, be due to 
differences in diet and exercise. In large part, exercise habits and food preferences are 
learned in childhood(22). Other factors affecting obesity risk are sex, age, smoking, 
education, socioeconomic status, racial group, and family history(23).  
The location of stored body fat is sexually dimorphic. Men have a greater 
propensity to store excess body fat as visceral adipose tissue, while women are more apt 
to store excess fat as subcutaneous adipose tissue, meaning overweight men have more 
fat between their organs while overweight women carry fat just under the skin; this 
sexual dimorphism increases with age(24). Visceral adipose tissue is thought to have a 
larger effect on metabolic state and overall health(24).  
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Obesity prevalence increases with increasing age through the 50’s, and begins to 
decline in the 60’s(23). The decline in later years may be due to a combination of a 
survivor’s effect and weight loss due to serious health conditions. The prevalence of 
obesity is lower for smokers (17.8%) than never smokers (20.9%) or former smokers 
(23.9%)(23). Weight gain is associated with smoking cessation and the amount of 
weight gained is correlated with cigarettes smoked per day(25).  
Education, socioeconomic status, income, and ethnicity have complex combined 
relationship with obesity. Obesity prevalence decreases with increasing level of 
education(23). Lower income is associated with increased obesity prevalence(26). 
African Americans have higher obesity rates than Hispanics which have higher rates 
than Caucasians(26). Ancestry contributes to obesity risk through differences in culture 
and genetics, but is confounded by disparities in income and education(26). Some of the 
differences may stem from differences in food availability, neighborhood walkability, 
and access to exercise facilities(26). 
Family history encompasses two factors, the common environment shared by 
people living together and genetics. Close relatives tend to have similar body shapes and 
sizes. This is reflected in the correlation of BMIs between different relationships as 
shown in Table 1. Twin studies yield higher heritability estimates (0.60-0.80) than 
family studies (0.30-0.60)(27); while adoption studies yield estimates similar to family 
studies in the absence of a common environment(28). Adoption studies, which look at 
monozygotic twins adopted by different families at birth, show that in the absence of a 
shared home environment, BMIs have a correlation of 0.66 to 0.70(29). A priori there 
are many factors and pathways likely to be involved in the risk of obesity with each 
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subject to alteration by genetic variation. These include genes involved in basal 
metabolic rate regulation, lipid metabolism, carbohydrate metabolism, and neurological 
factors involved in feeding and exercise behaviors(30). Identification of these genes, 
however, has proven to be challenging, however one example of a pathway that has 
repeatedly been implicated in obesity is the leptin-melanocortin pathway.  
Relationship Correlation 
Monozygotic twins 0.74 
Dizygotic twins 0.32 
Full siblings 0.24 
Parent-offspring 0.19 
Spouses 0.12 
Table	1.	BMI	correlation	between	relatives. Pooled estimates across studies come 
from Maes et al. (27) 
Underlying Signaling Pathways 
While many mechanisms are plausible, most variants identified so far associated 
with obesity are in genes relating to the leptin-melanocortin pathway (shown in Figure 
3), which is involved in hunger and satiety. Leptin, a hormone secreted by adipose 
tissue, travels through blood to the arcuate nucleus of the hypothalamus where it binds to 
the leptin receptor (LepR) in two types of cells to decrease food intake through two 
distinct pathways, the anorexigenic pathway and orexigenic pathway(31). In the 
anorexigenic pathway, leptin binding to the leptin receptor induces transcription of 
proopiomelanocortin (POMC), which is then cleaved into α-MSH and β-MSH by 
prohormone convertase 1(PC1)(32). α-MSH and β-MSH travel to the paraventricular 
nucleus of the hypothalamus and signal through the melanocortin 4 (MC4R) and 
melanocortin 3 (MC3R) receptors to inhibit food intake and decrease fat storage(32). 
This is accomplished through unknown mechanisms that involve Single-minded 
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homolog 1 (Drosophila) (SIM1), nucleobindin 2 (NUCB2), brain derived neurotrophic 
factor (BDNF) and Tyrosine receptor kinase B (TrkB) that is encoded by NTRK2(32). In 
the orexigenic pathway, the binding of leptin to the leptin receptor inhibits agouti related 
protein (AgRP) expression in the arcuate nucleus of the hypothalamus(32). AgRP acts as 
an antagonist of α-MSH by binding MC3R and MC4R, inhibiting signaling of satiety 
through these receptors(32). NPY is produced in the same neurons as AgRP(33). In 
mice, the NPY is released in the paraventricular nucleus of hypothalamus and results in 
increased production of corticotropin-releasing factor and subsequent activation of the 
hypothalamic pituitary adrenal axis which controls cortisol levels and the “fight or flight 
response” to stress. (34). NPY is down regulated with increased leptin levels(33). 
Disruption of the leptin-melanocortin pathway can result in obesity, as demonstrated by 
several monogenic obesity disorders where mutations in these pathway genes lead to 
severe obesity. This pathway demonstrates the complex relationship between genes and 
their gene products. The complexity and redundancy of pathways contributes to the 
difficulty of identifying genes and variants that contribute to obesity but whose effects 
may be masked by the complex relationships between gene products. 
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Figure	3. Leptin- Melanocortin Pathway.	Image adapted and expanded from	Beckers,	
S.,	D.	Zegers,	L.	F.	Van	Gaal,	and	W.	Van	Hul.	2009.	The	role	of	the	leptin‐
melanocortin	signalling	pathway	in	the	control	of	food	intake.	Critical	reviews	in	
eukaryotic	gene	expression	19:267‐287.(32). Abbreviations: ARC: Arcuate nucleus of 
hypothalamus, LepR: leptin receptor, POMC: proopiomelanocortin, PC1: prohormone 
convertase 1, AgRP: agouti related protein, NPY: neuropeptide Y, α-MSH: alpha 
Melanocyte stimulating hormone, β-MSH: beta Melanocyte stimulating hormone, PVN: 
paraventricular nucleus of hypothalamus, MC3R: melanocortin 3 receptor, MC4R: 
melanocortin 4 receptor, NUCB2: nucleobindin 2, SIM1: involve Single-minded 
homolog 1 (Drosophila), CRF: corticotropin-releasing factor, BDNF: brain derived 




In addition to common obesity, there are single gene disorders that cause obesity 
or lipodystrophy, sometimes in the context of a more complex syndrome (Table 2). 
Monogenic forms of obesity are typically characterized by being extreme and very early 
onset. Many of the genes implicated in single gene disorders are also part of the leptin 
melanocortin pathway and are characterized by hyperphagia. Mutations in MC4R result 
in the most common form of monogenic obesity, occurring in up to 6% of individuals 
with severe childhood obesity, meaning a BMI z-score ≥ 3 standard deviations from the 
age and sex specific mean (35, 36). Leptin (LEP) and leptin receptor (LEPR) mutations 
are perhaps the best-recognized genes due to parabiosis experiments involving the first 
murine obesity models. ob/ob (LEPR homolog) and db/db (LEP homolog) knock out 
mice are phenotypically similar; the mice are hyperphagic, develop morbid obesity and 
diabetes(37). When sewn together so as to share their circulatory systems with either a 
wild-type or db/db mouse, an ob/ob mouse decreases food intake, lose weight, and have 
decreased blood sugar levels; when paired with the db/db mouse, these effects are so 
severe that the ob/ob mouse can die of starvation without intervention(37). In contrast, 
db/db mice, paired with either wild-type or ob/ob mouse, continue to gain weight in the 
form of adipose tissue while its partner starves to death(37). Similarly, humans with 
mutations in both copies of LEP, develop severe obesity in early childhood characterized 
by hyperphagia, but respond to treatment with leptin injections(38).  
Lipodystrophy is class of metabolic disorders characterized by the loss of body 
fat and sometimes localized accumulation of body fat. Both monogenic forms and 
acquired forms (see Table 2) have been reported(39). Lipodystrophy patients have 
 11	
complications of insulin resistance, hepatic steatosis, and hypertriglyceridemia, 
highlighting that adipose tissues is metabolically active(39).  
The third class of monogenic obesity disorders is syndromic disease. These 
diseases occur with an array of other traits specific to each disorder (see Table 2). Many 
monogenic disorders include intellectual disability, hypogonadism, malformations of 
organs, and bone deformities. For example Bardet-Beidel syndrome, which is a 
ciliopathy characterized by renal abnormalities, retinal degeneration, polydactyly, central 
obesity, and intellectual disability(40), is a genetically heterogeneous disease, with 19 
different genes implicated thus far. Some of these genes form the BBSome, which is a 
molecule involved in signaling receptor trafficking to the cilia(41). Wilms tumor, 
aniridia, genitourinary anomalies, intellectual disability, and obesity (WARGO), is 
caused by a deletion in 11p13; deletions that include genes WT1, PAX6, and BDNF 
include an obesity component of the disease(42). These are just two examples of the 35 
syndromes that include obesity as a key feature. While monogenic obesity, syndromic 
obesity, and genetic forms of lipodystrophy provided insight into the pathways 
contributing to fat mass and distribution, these account for only small fraction of obesity 
cases, but common variants in or near some of these genes have been implicated in 
common obesity as discussed below. 
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Table 2. Monogenic forms of obesity, lipodystrophy, and syndromic obesity. 
monogenic disease characteristics implicated genes mode of 
inheritance 
references 
Monogenic obesity (isolated) hyperphagia, severe early onset obesity BDNF, CRHR1, CRHR2, 
LEP, LEPR, MCHR1, 
MC3R, MC4R, MRAP2, 





lipoatrophic diabetes, acanthosis nigricans, 
large hands and feet, lipemia, 
hepatosplenomegaly, insulin resistance 





partial lipodystrophy, insulin resistance  CIDEC AR (44)  
Familial partial 
lipodystrophy (FPL) 
loss of subcutaneous fat; fat accumulation 
in face, insulin resistance 






annular erythematous plaques, partial 
lipodystrophy, immune dysregulation, 
recurrent fever, muscle weakness 
PSMB8 AR (45, 46) 
Carbohydrate-deficient 
glycoprotein syndrome type 
1a 
hypotonia, hyporeflexia, trunk ataxia, 
growth retardation, lipodystrophy of the 
buttocks 
PMM2 AD (47)  
Hutchinson-Gilford progeria short stature, low body weight, early hair 
loss, lipodystrophy, scleroderma, aged 
facial features, decreased joint mobility 
LMNA AD, some AR (48)  
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(MAD), Type A 
growth retardation, craniofacial anomalies, 
mandibular hypoplasiam, lipodystrophy 
with acral loss of fatty tissue 
LMNA AR (49)  
Mandibuloacral dysplasia 
(MAD), Type B 
small chin, nose, and mouth, thin facial 
skin, skeletal anomalies, generalized 
lipodystrophy,  
ZMPSTE24 AR (50) 
Achondroplasia short-limb dwarfism, characteristic facies, 
obesity 




resistance to parathyroid hormone, 
thyroid-stimulation hormone, and 
gonadotropins; short stature, obesity, 
round facies, subcutaneous ossifications, 




Alstrom syndrome blindness, sensorineural hearing loss, 
childhood obesity, hyperinsulinemia, type 
2 diabetes 
ALMS1 AR (53)  
Angelman syndrome with 
obesity 
developmental delays, movement/balance 
disorder, frequent laugher/smiling, speech 




Atypical progeroid syndrome lipodystrophy and progeroid syndrome LMNA AD (55)  
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monogenic disease characteristics implicated genes mode of 
inheritance 
references 
Bardet-Biedl syndrome renal abnormalities, polydactyly, retinal 
degeneration, obesity 
 ARL6, BBIP1, BBS1, 
BBS10, BBS12, BBS2, BBS4, 
BBS5, BBS7, BBS9, 
WDPCP, CCDC28B, 
CEP290, IFT27, LZTFL1, 
MKKS, MKS1, TMEM67, 
SDCCAG8, TRIM32, TTC8 
varies, mostly AR (56-60) 
Borjeson-Forssman-
Lehmann syndrome 
severe mental defect, epilepsy, 
hypogonadism, hypometabolism, obesity, 
characteristic facies,  
PHF6 X-linked (61)  
Brachydactyly mental 
retardation syndrome 
short stature, stocky build, intellectual 
disability, brachymetaphalangia, eczema, 
obesity 
GPR35, AD (62) 
Carney complex with 
primary pigmented nodular 
adrenocortical disease and 
Cushing's syndrome 
tumors, myxomas in the heart, endocrine 
tumors, Cushing's syndrome, weight gain 
PRKAR1A AD (63) 
Carpenter Syndrome 1 acrocephaly, peculiar facies, 
brachydactylyl, congenital heart defects, 
intellectual disability, hypogenitalism, and 
obesity 
RAB23 AR (64)  
Carpenter Syndrome 2 craniosynostosis, polysyndactly, obesity, 
umbilical hernia, cryptochidism, 
congenital heart disease 
MEGF8 AR (65)  
Choroideremia with deafness 
and obesity 
 CHM, DFN3 X-linked (66) 
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monogenic disease characteristics implicated genes mode of 
inheritance 
references 
Cohen syndrome psychomotor retardation, clumsiness, 
microcephaly, hypotonia and joint laxity, 
progressive retinochoroidal dystrophy, 
thick hair, short philtrum, characteristic 
facies, obesity 
VPS13B AR (67)  
Combined pituitary hormone 
deficiency 
panhypopituitary dwarfism, deficiency of 
pituitary hormones, increased weight,  




hyperandrogenism, males: precocious 
pseudopuberty; females: hirsutism, 
oligomenorrhea, infertility, overweight 
H6PD complex (69) 
Fanconi-Bickel syndrome hepatorenal glycogen accumulation, 
proximal renal tube dysfunction, impaired 
glacatose and glucose utilization, facial 
obesity, lipodystrophy 
SLC2A2 AR (70) 
Fragile X syndrome with 
Prader-Willi-like phenotype 
intellectual disability, obesity, anal atrasia FMR1 X-linked (71) 
Insulin resistance syndromes severe insulin resistance, acanthosis 
nigricans, accelerated growth, obesity, 
polycystic ovary syndrome 
INSR AD, some AR (72)  
Isolated growth hormone 
(GH) deficiency 
dwarfism, delay bone maturation, 
micropenis, fasting hypoglycemia, truncal 
obesity, young facial appearance, high 
pitched voice 
GH1, GHRHR AR, some AD (73) 
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monogenic disease characteristics implicated genes mode of 
inheritance 
references 
MEHMO syndrome intellectual disability, epileptic seizures, 
hypogonadism and hypogenitalism, 
microcephaly, and obesity 
MEHMO X-linked (74)  
Mental retardation X-linked, 
syndromic 16 
intellectual disability, emotional 
disturbances, hypotonia, obesity, and 
gynecomastia 
MECP2 X-linked (75) 
Mental retardation X-linked, 
syndromic 7 
intellectual disability, obesity, 
hypogonadism, and tapering fingers 
MRXS7 X-linked (76) 
Mental retardation, X-linked, 
syndromic 11 
intellectual disability, characteristic facial 
dysmorphic features, obesity, large testes  
MRXS11 X-linked (77) 
Multiple endocrine neoplasia, 
type 1 with Cushing's disease 
tumors of endocrine tissues, including 
pituitary and adrenal tumors 
MEN1 AD (78) 
Prader-Willi syndrome decreased fetal activity, intellectual 
disability, short stature, hypogonadotropic 
hypogonadism, small hands and feet, 
obesity 
GABRG3, IPW, MAGEL2, 







hypotonia, progressive obesity, delayed 
developmental milestones, small 
extremities 
SIM1 AD (80) 
Prader-Willi-like syndrome, 
X-linked 
hypogenitalism, obesity, intellectual 
disability 
PWLSX X-linked (81) 
Simpson-Golabi-Behmel 1 pre- and postnatal overgrowth, congenital 
heart defects, coarse facies. 
GPC3, GPC4 X-linked (82, 83) 
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monogenic disease characteristics implicated genes mode of 
inheritance 
references 
Simpson-Golabi-Behmel 2 developmental delay, macrocephaly, early 
death, intellectual disability, dysmorphic 
facies, obesity 
OFD1 X-linked (84)  
Thyroid hormone resistance 
syndrome 
Resistance to thyroid hormone, goiter, 
short stature, obesity 
THRB AR (85) 
Ulnar-Mammary (Schinzel) 
syndrome 
ulnar-ray defects, small penis, delayed 
puberty, obesity, abnormal breast 
development 
TBX3 AD (86) 
WAGR syndrome with 
obesity 
Wilms tumor, aniridia, genitourinary 
anomalies, intellectual disability, and 
obesity 
11p13 deletion including 
PAX6, WT1, BDNF 
AD (42) 
Wilson-Turner syndrome dysmorphic facial features, hypogonadism, 
short stature, truncal obesity, severe 
intellectual disability 
HDAC8 X-linked (87) 
Table 2. Monogenic forms of obesity, lipodystrophy, and syndromic obesity.  
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Genetics of Common Obesity 
Investigations of monogenic and syndromic obesity and lipodystrophy have 
identified several genes, including many from the leptin melanocortin pathway, capable 
of causing obesity. These studies certainly demonstrate that genes cause obesity, but 
carriers of these mutations represent only a small proportion of obese people. To identify 
genes involved in the common forms of obesity in humans, over 500 candidate gene 
studies, 95 genome-wide linkage studies, and 43 genome-wide association studies 
(GWAS) with obesity-related traits have been performed(88). The results of these 
studies have established associations with obesity-related traits on all 22 autosomes and 
the X chromosome(88). The linkage studies, in particular, implicate broad regions of the 
genome not specific variants and genes. Genome wide SNP arrays began to dominate the 
field in 2005. The 43 genome wide association studies published to date on obesity and 
adiposity related traits have identified 305 variants at 167 loci associated with an obesity 
related trait at P < 5×10-8 (Figure 4)(89-131). Key findings include associations with 
variants in and near genes that are part of the leptin-melanocortin pathway, including 
MC4R, BDNF, and PCSK1 as well as many other genes, such as LYPLAL1, NEGR1, and 
NRXN3, that are also expressed in the brain and thought to be involved in hunger and 
satiety pathways(21).  
Two additional well-replicated loci are FTO and INSIG2. A signal in the 
noncoding region of FTO was initially attributed to the FTO gene, due to increased fat 
mass in murine models in which increased FTO expression was induced (132, 133). 
Despite this, the BMI increasing variants have not been connected to changes in FTO 
expression or function. These variants are eQTLs for the neighboring gene, IRX3(134). 
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Smemo et al. show that the BMI associated region of FTO interacts with the promoter of 
IRX3 altering the expression pattern(134). Further support for the role of IRX3 in body 
fat mass comes from knock out murine models that demonstrate a 25-35% decrease in 
body mass in comparison to wild type(134). For this locus the field has been able to 
elucidate a mechanism, through the IRX3 gene, albeit the field was initially dominated 
by FTO studies themselves. This is an exception, however, as generally linkage and 
genome wide chip arrays leave us with broad regions of the genome associated with the 
trait and no causal variant or gene.  
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Figure 4. Obesity Loci Identified by GWAS. Loci identified as being associated with 
obesity-related traits at p value< 1x10-8 are indicated with blue triangles. Monogenic 
adiposity loci are indicated by red triangles. Variants within 1 mega-base are represented 
only once(135).While genome-wide chip data provide an agnostic look, the hypothesis 
that coding variants are more likely to alter gene function justifies looking more closely 
at coding variation. As the cost of sequencing has decreased, there has been a recent 
influx of data in the form of whole genome sequencing, whole exome sequencing, and 
an array targeting low frequency variation seen by exome sequencing data 
(http://genome.sph.umich.edu/wiki/Exome_Chip_Design). To date no large-scale exome 
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array or exome sequencing studies have been published for adiposity traits, although 
these studies are currently underway. 
With the increasing prevalence of obesity, it is important to understand the 
genetic basis of disease. Each gene involved in obesity represents a potential mechanism 
that could be exploited to treat obesity. Heritability estimates indicate there is a 
substantial role for genetic variation, however currently identified genes and variants 
explain less than 3% of the variance in BMI(130). Large-scale studies have investigated 
associations of common variation and only the most basic measures of obesity, BMI and 
WHR, in predominately European samples. To identify novel associations, the work 
presented here utilizes additional adiposity measures, rare coding variants as well as 
common variants in Hispanics from Starr County, Texas.  
Starr County Health Studies 
 To investigate the role of genetic variation in the amount and distribution of body 
fat, a sample of non-diabetic individuals from Starr County, Texas will be used. Starr 
County, Texas lies along the Texas-Mexico border, approximately 100 miles inland from 
the Gulf of Mexico. The population of Starr County is over 95% Hispanic(136).The 
population is overwhelmingly poor, with over 40% of individuals living below the 
poverty line; the median income between 2008 and 2012 being just $24,653(136). The 
combination of homogenous low income and single ancestry composition makes this an 
ideal population for genetic studies.  
The contemporary Mexican-American population is the result of admixture of 
Native Americans, Europeans and Africans. Ancestry was computed for genome-wide 
array data using the 1000 Genomes reference populations using ADMIXTURE 
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(http://www.genetics.ucla.edu/software/admixture/)(137, 138). On average in Starr 
County, Mexican-Americans have 61% European Ancestry, 37% Native American 
Ancestry, and 2% African Ancestry. This is similar to previous reports in this population 
using microsatellite markers and blood groups(139, 140).  
Epidemiological studies in Mexican-Americans in Starr County started in 1981. 
These early studies looked at familial aggregation of diseases including type 2 
diabetes(141), gallbladder disease(142), and hypertension(143). These studies showed an 
exceptionally high prevalence of type 2 diabetes resulting in a long-term focus on 
diabetes, its complications, risk factors, and interventions(144-147).  
From 2002-2006 a group of 1,345 individuals were sampled from the population 
to be representative of adults in Starr County not diagnosed with type 2 diabetes (148). 
During this study, subjects underwent an oral glucose tolerance test, electrocardiogram, 
anthropometrics measurement, blood pressure determination, and collection of blood 
samples. All of these individuals were invited to take part in a second study occurring 
from 2010-2013; 57% of individuals took part in this subsequent study. During the 
second visit, most of the same measures as before were obtained as well as additional 
measures including cardiovascular measures from an echocardiogram and an in-home 
sleep study. The individuals participating in these two examinations form the sample for 
study in this dissertation. 
Because obesity is a major risk factor for developing type 2 diabetes, it has been 
studied through the years in the Starr County Health Studies. One of the first genetic 
studies of obesity in Starr County was an affected sib-pair study that looked for linkage 
between the Leptin gene and obesity(149).While there was no evidence of linkage with 
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obesity in this study, a later study which used families, did find linkage between Leptin 
variation and waist to hip ratio (WHR)(30). This larger study also found evidence of 
linkage between obesity and NPY, but no evidence of linkage for several other candidate 
genes including LEPR, GLP1R, and UCP1(30).  
More recently, association signals from large-scale genotyping studies have been 
replicated in samples from Starr County. For example, Herbert et al. identified 
rs7566605, a variant near INSIG2, associated with BMI in both children and adults(150). 
Replication efforts, including data from Starr County did not find evidence of 
association with this variant and an array of adiposity traits including obesity, BMI, 
weight, waist circumference and WHR(151). The variability of replication of this variant 
across studies has been the subject of much discussion. A meta-analysis looked at 
sources of heterogeneity across studies(152). Heid et al. found evidence that the effect is 
largest when comparing normal weight individuals to individuals with extreme obesity.  
Here I will expand on the obesity related analyses in Starr County. First I will 
investigate measures of obesity using multivariate techniques to capture overall 
adiposity and distribution of fat. I will then carry these measures forward as outcome 
variables for genetic analyses, using both genome-wide array and whole exome 
sequencing data. In addition to standard single variant analyses, gene-based analyses that 
aggregate signal across a gene, accounting for linkage across sites in the case of common 
variants will be utilized. Finally I will investigate the array of variation in genes known 
to cause monogenic obesity disorders. 
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Chapter 2: Alternative obesity measures 
INTRODUCTION 
 While obesity is defined as having a body mass index of at least 30 kg/m2, it is 
actually excess adipose tissue that is associated with the risk of comorbidities. The ease 
with which BMI can be calculated makes it an attractive measure; however, it essentially 
is only weight adjusted for height and does not account for either the type of tissue or fat 
distribution. Two individuals with the same BMI can have very different body 
compositions. For example, athletes are often classified as overweight or obese despite 
having low amounts of adipose tissue and increased muscle mass(153). In Starr County, 
data show that individuals with the same BMI can have markedly different 
distribution/disease profiles. Therefore, it seems prudent to examine alternative measures 
of obesity and fat distribution that may more adequately reflects the underlying 
biological processes. Measures that better reflect the underlying biological processes 
may be more amenable to discover the genetic effects. In this chapter, alternative 
composite measures of obesity are explored. 
Percent body fat quantifies the proportion of adipose tissue in an individual’s 
body. The gold standard for calculating body fat is through medical imaging such as 
dual-energy X-ray absorptiometry (DEXA) or magnetic resonance imaging (MRI); 
however, both of these involve expensive medical equipment, require specialized 
training and expose subjects to radiation(24, 154). Bioelectrical impendence analysis is a 
proxy for percent body fat. Bioelectrical impendence analysis is obtained sending a 
small electrical current through the body and measuring resistance and reactance(155). 
This can be done using small portable devices that require little training. Scales utilizing 
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this technology can now be readily purchased for home use. Offsetting the advantages of 
bioimpedance is the fact that it is sensitive to factors such as dehydration. Even so 
estimates of percent body fat derived from bioimpedance have a correlation greater than 
0.9 with measures from DEXA(155). As with BMI, quantifying the amount or percent of 
adipose tissue does not specify where the adipose tissue is. 
Adipose location and type are important considerations, because deposits in 
different regions of the body have varying metabolic properties. For example, 
subcutaneous adipose tissue is thought to have a lesser role in the risk of developing 
comorbidities whereas excess visceral adipose tissue increases risk for an array of 
metabolic disease such as cardiovascular disease and type 2 diabetes(24). To better 
capture the distribution of body fat, measures such as circumferences and skin folds are 
used. Waist circumference and waist to hip ratio reflect central adiposity, but they are 
correlated with BMI(156). Adjusting for BMI has led to the successful identification loci 
specific to central adiposity(107, 157). Mid upper arm circumference is a measure of 
subcutaneous adipose tissue(158). Another measure of subcutaneous adipose tissue is 
skin fold thickness at a variety of anatomical sites. Skin fold measures have poor 
reproducibility and are more difficult to obtain in obese individuals(159).  
BMI and other single measures of adiposity and adiposity distribution are limited 
in their ability to capture the amount of fat and fat distribution simultaneously. The 
confounding and correlation between these measures is likely to hinder the identification 
of loci and variants. Previously, principal components analyses and factor analyses of 
skinfold measures, percent body fat, body circumferences, BMI, and ratios between 
some of these measures have identified factors that have an independent genetic basis 
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and represent total obesity, subcutaneous fat, or fat distribution between extremities and 
trunk (160-163). 
While the Starr County data does not contain skinfolds, and thus cannot be 
directly compared to any of these prior studies, the multiple circumferences, BMI, and 
percent body fat allow the use of principal components to create composite measures of 
obesity that capture both magnitude and distribution of adiposity. 
METHODS 
In the Starr County Health Studies, measurements of mid upper arm, hip, and 
waist circumferences, height, weight and bioimpendance were assessed at two visits an 
average of 8.5 years apart. Waist measurements were taken to the nearest 10th of a 
centimeter (cm) while holding a tape measure horizontal to the ground at the umbilicus. 
An observer verified the tape measure remained horizontal. Hip measurements were 
taken at the widest circumference to the nearest 10th of a cm. Arm circumference was 
measured half way between the shoulder and elbow to the nearest 10th of a cm. Height 
was measured without shoes using a wall-mounted stadiometer to the nearest 10th of a 
cm. Weight was measured to the nearest 10th of a kilogram using a balance beam scale. 
These were used to calculate BMI. Weight at age 18 and weight at maximum were both 
self reported, and measured height was used to calculate BMI. Bioimpedance was 
measured using a bioimpedance device from RJL Systems (Clinton Township, NJ). Fat 
free mass, and subsequently percent body fat, were then calculated using the equations 
of Segal et al.(155). The average and standard error for each of these measurements at 
each visit and the correlation between the two visits are presented in Table 3, excluding 
individuals diagnosed with type 2 diabetes prior to the visit or without genetic data. 
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Individuals that meet diagnostic criteria for type 2 diabetes at the study visit are retained 
in analyses, because they have not been exposed to diabetes treatments that alter body 
composition. On average, individuals gained 3 kg, 1.6 cm on the hips and 5.1 cm on the 
waist between visits. 
		 VISIT 1 VISIT2 correlation 
Sample size 825 438 - 
Newly diagnosed T2D 5.40% 9.50% - 
Percent female 71% 76% - 
Age (years) 39.6 (9.6) 48.5 (8.9)  - 
Weight (kg) 79.3 (18.5) 81.3 (18.1) 0.90 
Height (cm)  161.6 (8.7) 160.3 (8.2) 0.98 
BMI (kg/m2) 30.3 (6.3) 31.7 (6.6) 0.89 
BMI at age 18 - 23.4 (4.9) - 
BMI at maximum - 35.1 (7.7) - 
Waist circumference (cm) 97.1 (15.0) 105.8 (15.5) 0.82 
Hip circumference (cm) 109.2 (12.5) 112.1 (13.9) 0.87 
WHR 0.89 (0.08) 0.91 (0.07) 0.72 
Percent body fat 32.1 (10) 34.8 (9.7) 0.86 
Arm circumference (cm) 32.9 (4.6) 33.8 (4.9) 0.80 
Table 3. Characteristics of samples at each visit. Means and standard deviations are 
given for each anthropometric measure at each of two study visits. The Pearson’s 
correlation coefficients between measures from the two visits are given in the last 
column. 
Each measure of adiposity has its own strengths and weaknesses. To capture a 
composite of these measures, I combined all the measures at each visit using principal 
components analysis (PCA). Here, the correlation matrix was used since variables have 
different scales. PCA transforms the original set of N measures into N uncorrelated 
linear combinations with the first accounting for the largest proportion of variation and 
the Nth accounts for the least variation. Each principal component is orthogonal 
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(uncorrelated) to each prior component. For each time point I utilized five measures: 
BMI, percent body fat, waist, hip, and arm circumferences. 
RESULTS 
The proportion of variance explained by each principal component is in Table 4. 
The similarity between the principal components analysis for the two visits is striking. 
For visit 1 and visit 2, the first principal component, which accounts for 82.3% and 
82.6% of the variation, respectively, is strongly correlated with BMI (r2 = -0.98 and -
0.97, respectively) as shown in Tables 5 and 6 and plotted in Appendix Figures 1 and 2. 
The first principal component has similar loadings, the weight each variable has in the 
component, for all five of the correlated obesity measures Tables 5 and 6. 
 proportion of variance 
explained 
 VISIT 1 VISIT 2 
PC1 0.823 0.826 
PC2 0.092 0.089 
PC3 0.050 0.047 
PC4 0.025 0.026 
PC5 0.010 0.012 
Table 4. Proportion of variance explained by each principal component.  
	  	   	  	   Comp.1 Comp.2 Comp.3 Comp.4 Comp.5 	  	   scaling loading corr. loading corr. loading corr. loading corr. loading corr. 
BMI 6.292 -0.483 -0.980 0.000 0.010 0.000 -0.007 0.000 0.019 0.874 0.200 
waist 15.016 -0.440 -0.890 0.469 0.320 -0.525 -0.260 0.476 0.170 -0.289 -0.065 
hip 12.484 -0.466 -0.950 0.000 -0.030 -0.271 -0.140 -0.814 -0.290 -0.212 -0.048 
PBF 0.100 -0.405 -0.820 -0.822 -0.560 0.000 0.014 0.327 0.120 -0.230 -0.052 
arm 4.641 -0.437 -0.890 0.320 0.220 0.806 0.400 0.000 0.009 -0.236 -0.053 
Table 5. Principal component loadings and correlations for visit 1.	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		 		 Comp.1 Comp.2 Comp.3 Comp.4 Comp.5 
		 scaling loading corr. loading corr. loading corr. loading corr. loading corr. 
BMI 6.500 -0.480 -0.970 0.000 -0.028 0.000 0.008 -0.144 -0.052 0.867 0.210 
waist 14.348 -0.440 -0.890 -0.456 -0.300 0.572 0.280 0.482 0.180 -0.217 -0.049 
hip 12.826 -0.467 -0.950 0.000 0.066 0.226 0.110 -0.757 -0.280 -0.369 -0.096 
PBF 0.097 -0.408 -0.830 0.809 0.540 0.000 -0.024 0.403 0.150 -0.134 -0.030 
arm 4.659 -0.439 -0.890 -0.355 -0.240 -0.786 -0.380 0.105 0.380 -0.215 -0.057 
Table 6. Principal component loadings and correlations for visit 2.  
The second principal component accounts for 9.2% and 8.9% of the variance for 
visit 1 and visit 2 respectively; but unlike BMI is not strongly correlated with any one 
trait. The loadings for principal component 2 (PC2) are zero for both BMI and hip 
circumference. PC2 increases with increasing waist circumference, increasing arm 
circumference and decreasing percent body fat, resulting in a separation between males 
and females. The direction of the loadings is flipped for visit 2, but the magnitude is 
similar. PC2, although uncorrelated with hip circumference, is more correlated with 
waist to hip ratio than either waist circumference or arm circumference, as shown for 
visit 1 in Figure 5. PC2 separates men with excess abdominal fat from women with 
small waist to hip ratios. This indicates that PC2 appears to be capturing degree of 
central adiposity.  
PC3 captures 5% and 4.7% of the variation at visit 1 and visit 2, respectively. 









Figure 5. Relationship between PC2 and PC3 with adiposity measures for visit 1. 
The bottom half shows the scatter plot for each pair of traits, with PC2 in the bottom 
row. The upper half shows the Pearson correlation coefficient for the two measures. 
Histograms of the traits are displayed in the middle. Points are color coded by sex and 
obesity status. Obese males are dark blue; non-obese males are light blue; obese females 




Figure 6. Correlation between PC3 and arm to waist ratio at visit 1.  
	DISCUSSION 
Of the many measures of adiposity available, some are easier to obtain in the 
field than others. With the gold standards being derived from imaging that is cost-
prohibitive, alternative measures are more accessible. By combining multiple measures 
that require minimal equipment, I have created composite measures, PC2 and PC3. PC1 
is strongly correlated with BMI. Due to the loss of clinical interpretability when using 
the composite measure, BMI, not PC1, will be used as an outcome for genetic analyses. 
For PCA, BMI was not split into weight and height, because BMI represents a non-linear 
combination of the two traits. When including weight and height separately, the second 
principal captured height, instead of adiposity.  
PC2, like waist to hip ratio, exhibits marked sexual dimorphism. There are two 
sources of sexual dimorphism in these adiposity traits. The first is that there are real 







second comes from the equations used to calculate percent body fat, with four specific 
equations for males and females with and without obesity(155). To account for this, sex 
will be used as a covariate in all genetic analyses. 
PC2 polarized men with excessive abdominal fat from women with extremely 
low waist to hip ratios; this can be thought of as a measure of central adiposity. PC3 
separates those with excessive adiposity all over from those with high central adiposity 
and average arm circumferences and can be thought of as a measure of central versus 
peripheral adiposity. Similarly Comuzzie et al. found that in principal components 
analyses using skinfolds the first PC represents overall magnitude of skin folds, the 
second upper vs. lower subcutaneous adiposity, and the third central versus peripheral 
subcutaneous adiposity(163). Livshits et al.’s factor analysis of BMI, body fat, skinfolds, 
and circumferences resulted in four primary factors with factor 1 representing the skin 
folds, factor 2 representing total fat and BMI, factor 3 representing central adiposity 
distribution and factor 4 representing the subcutaneous fat on the trunk versus 
extremities(160). PC2 here is analogous to Comuzzie et al.’s PC 2 and Livshits et al.’s 
Factor 3, while PC3 here is analogous to Comuzzie et al.’s PC 3 and Livshits et al.’s 
Factor 4(160, 163). Both of these studies looked at the relationship between these traits 
across family members and found there is a significant genetic component(160, 163) 
By analyzing these composite measures, which I refer to as PC2 and PC3 
throughout, in addition to standard measures of adiposity I aim to identify loci that are 
involved in body fat distribution and overall adiposity.  
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Chapter 3: Genome wide SNP analysis 
INTRODUCTION 
 As previously discussed in chapter 1, obesity related traits have a high 
heritability. To better understand the genetic basis of obesity related traits at least 41 
genome-wide association studies have been completed. Traditionally, these studies have 
looked at the evidence that each individual variant is associated with obesity, BMI, waist 
circumference, or waist to hip ratio. With time the density of variants has increased. 
Early studies genotyped a mere 100,000 SNPs; today it is common to have over 10 
million variants after imputation, as we do here. 
While many associations have already been successfully identified, only 2.7% of 
the variation in BMI is explained(130). Factors such as different allele and haplotype 
frequencies in different populations, interaction with the environment, and distribution 
of the trait can give rise to different association signals. Utilizing an array of adiposity 
measures increases the power of this data set. Two multi-variate approaches will be used 
to leverage this data set. First, the composite measures of adiposity introduced in chapter 
2 will be utilized. Second, by meta-analyzing association results for array of adiposity 
traits while correcting for the correlation between the traits, we will be able to detect 
variants that have a pleiotropic effect. Further, beyond testing for association with each 
variant, we also test for a cumulative association across genes using versatile gene-based 
association study (VEGAS) (164). By utilizing VEGAS, we will be able to identify 
genes that have multiple variants associated with an outcome at levels lower than single 




 Genotyping: Genomic DNA isolated from whole blood from 1980 unique 
individuals form Starr County was genotyped on the Affymetrix Genome-Wide Human 
SNP Array 6.0 at the Center for Inherited Disease Research (CIDR). Genotypes were 
called with two algorithms, Birdseed v2(165) and corrected robust linear model with 
maximum likelihood classification (CRLMM)(166). Only calls that matched across the 
two algorithms were kept(167).  
 Sample subset: While samples were selected to be unrelated at close level, pair-
wise identity-by-decent (IBD) estimates were calculated in PLINK 
(http://pngu.mgh.harvard.edu/~purcell/plink/) and identified numerous related 
individuals(168). One individual from each related pair with an IBD>0.28 was removed. 
Individuals with type 2 diabetes were preferentially kept over controls. This unrelated 
subset was carried forward for additional genotyping, imputation and sequencing. For 
the sake of comparability across genetic datasets this unrelated subset has been used 
throughout.  
Imputation to 1000 Genomes: To expand the number of loci we have genetic 
information on, we imputed our hard calls out to the 1000 Genomes haplotypes-- Phase 
1 integrated variant set March 2012 release(137). Additional QC of genotyped data, 
including tests of Hardy-Weinberg disequilibrium and removal of ambiguous (A/T and 
G/C) variants were applied prior to imputation. This yielded a set of 643,446 scaffold 
variants. The Starr County Affymetrix genotypes were first phased using 
SHAPEIT(169), then imputed in 1 mega base sections with a 500 kilobase buffer using 
IMPUTE2 as part of the T2D-GENES project(170, 171). 
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Trait transformations: Within the unrelated subset of data, analyses were limited 
to individuals that were not diagnosed with type 2 diabetes prior to the time of the visit. 
This is due to the effects of many diabetes treatments, both medications and 
recommended changes in lifestyle, on weight and body fat. Residuals were calculated for 
each trait (BMI, WHR, waist circumference, hip circumference, arm circumference, 
percent body fat, and two composite measures of obesity, PC2 and PC3, at the two visits, 
and BMI at age 18 and maximum BMI) after adjusting for age at time of measurement 
and sex. For WHR, transformations were performed separately in males and females and 
with and without adjusting for BMI, resulting in a total of 28 outcomes. The residuals 
were rank-normalized to meet the assumption of normality, which is particularly 
important for low frequency and rare variant association tests. To obtain biologically 
meaningful effect sizes, analyses of the untransformed residuals were performed in 
parallel.  
Population structure: To account for population structure, genetic principal 
components were calculated using a set of variants directly genotyped that were not in 
linkage disequilibrium with each other. The principal components were calculated with 
in the unrelated dataset using EIGENSTRAT(172). 
Single variant analysis: Association of variants with phenotype residuals were 
analyzed using a linear regression model, which accounts for uncertainty in genotype 
imputation, implemented in SNPTEST v2.5 
(https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html) (173). To account 
for population structure, principal components were included as covariates in the model. 
Analyses were restricted to variants with an imputation information score of at least 0.7 
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and a minor allele count greater than five due to instability in models for very rare 
variants. Genome-wide significance was defined as P < 5 × 10-8, which corrects for the 
approximately one million independent genome wide tests(174). Lowering an order of 
magnitude to P < 5 × 10-7 was used as criteria for genome-wide suggestive associations. 
Multi-trait analysis To capture variants’ effects across the spectrum of adiposity 
traits, t-test statistics were meta-analyzed across all the traits correcting for the 
correlation between the test statistics using the software CPASSOC v.2(175, 176). 
 Gene-based analysis: Versatile Gene-based Association Study (VEGAS) was 
used to assess the association of variation across genes with adiposity traits(164). 
VEGAS, as implemented in FAST (https://bitbucket.org/baderlab/fast/wiki/Home), 
accounts for linkage between variants within each gene by first calculating the pairwise 
LD correlation matrix, then simulating multivariate normal vectors and calculating the 
simulated test statistic(177). Genes were defined as 20 kilobases in each direction from 
start and stop positions in NCBI build 37.3. Variants in the physical region with a minor 
allele frequency (MAF) > 0.01 and imputation info > 0.7 were included in the combined 
test. Additional gene-based tests including annotation information are utilized with the 
exome sequencing data in chapter 4. 
RESULTS 
Single Variant Associations: The single variant test statistics were well 
calibrated, after quality control measures of imputation information > 0.7 and minor 
allele count (MAC) > 5 were implemented. Quantile quantile (QQ) and Manhattan plots 
for the 24 traditional outcomes are in Figures 7 and 8, respectively. The genomic 
inflation factors (λ), which measures how well the p-values follow the expected 
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distribution under the null hypothesis of no association, range from 0.984 to 1.01, 
indicating that there is no systematic inflation of the test statistic and any population 
structure is adequately controlled for. Due to low sample size, the tendency towards 
deflated QQ plots, meaning there is less association than should be observed by chance 
alone, is expected. 
Variants that are significantly (P < 5 × 10-8) or suggestively (P < 5 × 10-7) 
associated with any of these 24 traditional obesity related analyses are in Table 7. A total 
of 5 significant associations at 2 loci were observed. Significant results include an 
association with low frequency variants in and near gamma-aminobutyric acid (GABA) 
A receptor, beta 2 (GABRB2) and decreased WHR at the second visit (P = 1.66 × 10-9, N 
= 434, β (SE) = -0.14 (0.02), MAF= 0.01, info=0.71). This association persists after 
adjusting for BMI. An association with increased waist circumference at the second visit 
and two rare variants in complete linkage disequilibrium (LD) upstream of SH2	domain	
containing	4A (SH2D4A) (index SNP rs180998363, P = 1.25 × 10-8, N = 497, β (SE) = 
42 (6.1), MAF= 0.01, info=0.75). 
There are also 56 suggestive association signals at 20 additional loci. A few 
highlights from biologically interesting genes including lipin1 (LPIN1) and percent body 
fat at visit 1, neuropeptide Y (NPY) with BMI at visit 1, polycystic kidney and hepatic 
disease 1 (PKHD1) and neural precursor cell expressed, developmentally down-
regulated 4-like E3 ubiquitin ligase (NEDD4L) with WHR at visit 1, SH3 and multiple 
ankyrin repeat domains2 (SHANK2) with maximum BMI, MACRO	domain	containing	2	
(MACROD2) with arm circumference. The betas are directionally consistent across the 
two visits for all traits. 
Figure 7. QQ plots for single variant association tests with imputed data. 38	  
    
    
    
    
arm visit 1 arm visit 2 
BMI visit 1 BMI visit 2 
BMI at 18 BMI at max 
hip visit 1 hip visit 2 
Figure 7. QQ plots for single variant association tests with imputed data. 39	  
    
    
    
    
percent body fat visit 1 percent body fat visit 2 
waist visit 1 waist visit 2 
WHR females visit 1 WHR females visit 2 
WHR males visit 1 WHR males visit 2 
Figure 7. QQ plots for single variant association tests with imputed data. 40	  
   
   
   
     
WHR visit 1 WHR visit 2 
WHR adjusted for BMI 
females visit 1 
WHR adjusted for BMI 
females visit 2 
WHR adjusted for BMI 
males visit 1 
WHR adjusted for BMI 
males visit 2 
WHR adjusted for BMI 
visit 1 
WHR adjusted for BMI 
visit 2 




arm circumference visit 1 arm circumference visit 2 
BMI visit 1 BMI visit 2 
BMI at age 18 BMI at maximum 
hip circumference visit 1 hip circumference visit 2 
Figure 8 Single variant Manhattan plots from genome-wide imputed data  42	  
   
percent body fat visit 1 percent body fat visit 2 
waist circumference visit 1 waist circumference visit 2 
WHR females visit 1 
WHR males visit1 
WHR females visit 2 
WHR males visit 2 
Figure 8 Single variant Manhattan plots from genome-wide imputed data  43	  
 
WHR visit 1 WHR visit 2 
WHR adjusted for BMI females visit 1 WHR adjusted for BMI females visit 2 
WHR adjusted for BMI males visit 1 
WHR adjusted for BMI visit 1 
WHR adjusted for BMI males visit 2 
WHR adjusted for BMI visit 2 
 44	
chr position Variant gene ref alt Trait Visit P  β (SE) info EAC N MAF 
1 202021786 rs74862838 ELF3(dist=35471), 
GPR37L1(dist=70243) 
T G WHR adj BMI v1 1.10 × 10-7 -0.036 (0.0073) 0.73 84 818 0.051 
v2 0.0039 -0.029 (0.0098) 0.72 50 434 0.057 
2 11823403 rs75618981 LPIN1 G A percent body 
fat 
v1 1.80 × 10-7 0.087 (0.02) 0.87 20 824 0.012 
v2 0.22 0.042 (0.027) 0.97 10 410 0.012 
2 11827803 rs191122460 LPIN1 C A percent body 
fat 
v1 2.80 × 10-7 0.086 (0.019) 0.93 20 824 0.012 
v2 0.21 0.042 (0.027) 0.99 10 410 0.012 
2 11870002 rs113485904 LPIN1 G A percent body 
fat 
v1 3.30 × 10-7 0.084 (0.019) 0.97 20 824 0.012 
v2 0.21 0.042 (0.027) 0.99 10 410 0.012 
2 11883170 rs112863316 LPIN1 T C percent body 
fat 
v1 1.80 × 10-7 0.086 (0.019) 0.91 21 824 0.013 
v2 0.31 0.038 (0.026) 0.84 11 410 0.014 
2 34707113 rs6543845 LINC01317(dist=184300), 
LINC01320(dist=195511) 
A G hip v1 0.014 2 (0.82) 0.75 1267 821 0.23 
v2 1.90 × 10-7 5.2 (1) 0.78 760 496 0.23 
2 34721460 rs7557071 LINC01317(dist=198647), 
LINC01320(dist=181164) 
A C hips v1 0.015 2 (0.82) 0.75 1271 821 0.23 
v2 1.20 × 10-7 5.3 (1.1) 0.77 763 496 0.23 
2 34722105 chr2:34722105:D LINC01317(dist=199292), 
LINC01320(dist=180519) 
TC T hip v1 0.024 1.8 (0.81) 0.75 1243 821 0.24 
v2 4.50 × 10-7 5 (1) 0.77 748 496 0.25 
2 34725422 rs13414227 LINC01317(dist=202609), 
LINC01320(dist=177202) 
G A hip v1 0.011 2.1 (0.81) 0.76 1263 821 0.23 
v2 1.70 × 10-7 5.2 (1) 0.77 757 496 0.24 
2 36152014 chr2:36152014:I LINC01320(dist=1204384), 
LOC100288911(dist=429878) 
T TA arm v1 4.90 × 10-7 -1.3 (0.27) 0.82 528 824 0.32 
v2 0.0023 -1.1 (0.35) 0.81 326 497 0.33 
2 203424027 rs75023458 BMPR2 A C WHR v1 2.90 × 10-7 -0.02 (0.0037) 0.73 1031 818 0.37 
v2 0.0015 -0.017 (0.0051) 0.69 554 434 0.36 
3 132406895 rs76967933 NPHP3-ACAD11 C A WHR v1 1.90 × 10-7 -0.035 (0.0069) 0.87 103 818 0.063 
v2 0.011 -0.022 (0.0081) 0.89 64 434 0.073 
3 132415424 rs76177059 NPHP3-ACAD11 T C WHR v1 1.90 × 10-7 -0.036 (0.007) 0.88 99 818 0.06 
v2 0.014 -0.022 (0.0083) 0.89 61 434 0.07 
3 132421998 rs79328618 NPHP3-ACAD11 G A WHR v1 3.50 × 10-7 -0.035 (0.0069) 0.9 99 818 0.06 
v2 0.012 -0.022 (0.0081) 0.91 61 434 0.07 
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chr position Variant gene ref alt Trait Visit P  β (SE) info EAC N MAF 
4 5844364 rs34613066 CRMP1 C T WHR females v1 0.2 0.014 (0.012) 0.8 42 579 0.036 
v2 1.90 × 10-7 0.069 (0.015) 0.76 24 330 0.036 
4 5844364 rs34613066 CRMP1 C T WHR adj BMI 
females 
v1 0.11 0.016 (0.011) 0.81 42 579 0.036 
v2 2.20 × 10-7 0.068 (0.014) 0.76 24 330 0.036 
4 59573143 rs142866966 LOC101928851(dist=1240991), 
NONE(dist=NONE) 
A G arm v1 8.20 × 10-8 5.2 (0.84) 0.71 48 824 0.029 
v2 4.00 × 10-5 4.8 (1) 0.71 34 497 0.034 
5 160597595 rs113244407 LOC285629(dist=231962), 
GABRB2(dist=117841) 
T G WHR v1 0.29 -0.0081 (0.014) 0.88 22 818 0.013 
v2 2.50 × 10-8 -0.11 (0.019) 0.8 12 434 0.013 
5 160597595 rs113244407 LOC285629(dist=231962), 
GABRB2(dist=117841) 
T G WHR females v1 0.45 -0.0038 (0.016) 0.89 18 579 0.015 
v2 7.60 × 10-8 -0.12 (0.021) 0.84 10 330 0.015 
5 160597595 rs113244407 LOC285629(dist=231962), 
GABRB2(dist=117841) 
T G WHR adj BMI 
females 
v1 0.65 -0.00013 (0.014) 0.9 18 579 0.015 
v2 1.70 × 10-7 -0.11 (0.021) 0.84 10 330 0.015 
5 160597595 rs113244407 LOC285629(dist=231962), 
GABRB2(dist=117841) 
T G WHR adj BMI v1 0.57 -0.0018 (0.012) 0.9 22 818 0.013 
v2 2.30 × 10-7 -0.098 (0.018) 0.85 12 434 0.013 
5 160689360 rs17456567 LOC285629(dist=323727), 
GABRB2(dist=26076) 
G A WHR v1 0.32 -0.0075 (0.014) 0.84 23 818 0.014 
v2 1.70 × 10-7 -0.1 (0.019) 0.8 12 434 0.014 
5 160689360 rs17456567 LOC285629(dist=323727), 
GABRB2(dist=26076) 
G A WHR females v1 0.49 -0.0031 (0.016) 0.85 19 579 0.016 
v2 2.70 × 10-7 -0.11 (0.021) 0.82 10 330 0.015 
5 160822038 rs112490216 GABRB2 G C WHR v1 0.29 -0.013 (0.013) 0.83 28 818 0.017 
v2 3.60 × 10-7 -0.11 (0.02) 0.74 13 434 0.015 
5 160831588 rs111330620 GABRB2 A G WHR v1 0.29 -0.013 (0.013) 0.83 28 818 0.017 
v2 3.50 × 10-7 -0.11 (0.02) 0.74 13 434 0.015 
5 160880879 rs150769823 GABRB2 C T WHR v1 0.16 -0.021 (0.015) 0.88 19 818 0.011 
v2 1.70 × 10-9 -0.14 (0.023) 0.72 10 434 0.012 
5 160880879 rs150769823 GABRB2 C T WHR adj BMI v1 0.3 -0.015 (0.013) 0.91 19 818 0.011 
v2 7.80 × 10-9 -0.14 (0.022) 0.71 10 434 0.012 
6 51934092 rs17638535 PKHD1 G A WHR adj BMI v1 1.10 × 10-7 -0.14 (0.028) 0.7 5 818 0.0032 
v2 0.026 -0.062 (0.031) 0.85 4 434 0.0044 
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chr position Variant gene ref alt Trait Visit P  β (SE) info EAC N MAF 
6 80291793 rs143783440 LCA5(dist=44646), 
SH3BGRL2(dist=49207) 
G A BMI at 18 v1 2.60 × 10-7 -1.4 (0.32) 0.85 362 825 0.22 
v2         
6 80307108 chr6:80307108:D LCA5(dist=59961), 
SH3BGRL2(dist=33892) 
GAGGA G BMI at 18 v1 2.90 × 10-7 -1.5 (0.33) 0.91 276 825 0.17 
v2             
6 163490679 chr6:163490679:D PACRG GCA G WHR v1 2.70 × 10-7 0.016 (0.0033) 0.95 756 818 0.46 
v2 0.013 0.01 (0.0042) 0.94 395 434 0.45 
7 24093468 rs116467353 STK31(dist=221338), 
NPY(dist=230339) 
C T BMI v1 2.50 × 10-7 -7.9 (2.1) 0.71 11 825 0.0064 
v2 0.061 -5.1 (3.3) 0.82 4 438 0.0051 
8 19170363 rs180998363 SH2D4A A G waist v1 0.0099 14 (3.8) 0.84 19 822 0.011 
v2 1.20 × 10-8 42 (6.1) 0.75 8 497 0.0085 
8 19170364 rs185529143 SH2D4A G C waist v1 0.0099 14 (3.8) 0.84 19 822 0.011 
v2 1.20 × 10-8 42 (6.1) 0.75 8 497 0.0085 
11 71042064 rs71473821 SHANK2(dist=106222), 
FLJ42102(dist=74728) 
G A BMI at max v1 1.70 × 10-7 -10 (2.4) 0.99 10 809 0.0062 
v2         
11 71057262 rs34212157 SHANK2(dist=121420), 
FLJ42102(dist=59530) 
C T BMI at max v1 1.70 × 10-7 -10 (2.4) 0.99 10 809 0.0062 
v2             
11 74066524 rs61902400 PGM2L1 G A WHR v1 0.021 0.0076 (0.0035) 0.79 785 818 0.48 
v2 3.20 × 10-7 0.022 (0.0046) 0.76 413 434 0.48 
12 124021547 rs74924067 MIR3908 C T hip v1 3.70 × 10-7 -6 (1.3) 0.73 150 821 0.091 
v2 0.00076 -5.4 (1.7) 0.71 88 496 0.089 
12 127088883 rs1541486 LOC100128554(dist=131552), 
LOC100996671(dist=48609) 
C T WHR v1 0.032 0.0077 (0.0037) 0.85 493 818 0.3 
v2 2.10 × 10-7 0.024 (0.0048) 0.86 256 434 0.3 
12 127088883 rs1541486 LOC100128554(dist=131552), 
LOC100996671(dist=48609) 
C T WHR adj BMI v1 0.014 0.0078 (0.0033) 0.86 493 818 0.3 
v2 2.90 × 10-7 0.023 (0.0046) 0.86 256 434 0.3 
12 127088883 rs1541486 LOC100128554(dist=131552), 
LOC100996671(dist=48609) 
C T WHR adj BMI 
females 
v1 0.0082 0.01 (0.0042) 0.86 357 579 0.31 
v2 3.40 × 10-7 0.027 (0.0056) 0.85 195 330 0.3 
12 127088883 rs1541486 LOC100128554(dist=131552), 
LOC100996671(dist=48609) 
C T WHR females v1 0.022 0.01 (0.0046) 0.85 357 579 0.31 
v2 4.70 × 10-7 0.027 (0.0057) 0.85 195 330 0.3 
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chr position Variant gene ref alt Trait Visit P  β (SE) info EAC N MAF 
12 127092972 rs4765418 LOC100128554(dist=135641), 
LOC100996671(dist=44520) 
T G WHR v1 0.11 0.0054 (0.0035) 0.97 511 818 0.31 
v2 4.80 × 10-7 0.021 (0.0045) 0.98 263 434 0.3 
12 127093438 chr12:127093438 LOC100128554(dist=136107), 
LOC100996671(dist=44054) 
C T WHR v1 0.078 0.0059 (0.0034) 1 493 818 0.3 
v2 3.60 × 10-7 0.021 (0.0044) 1 254 434 0.29 
12 127094364 chr12:127094364:D LOC100128554(dist=137033), 
LOC100996671(dist=43128) 
CTT C WHR v1 0.19 0.0046 (0.0037) 1 368 818 0.23 
v2 3.80 × 10-7 0.023 (0.0048) 1 193 434 0.22 
12 127094542 rs11058745 LOC100128554(dist=137211), 
LOC100996671(dist=42950) 
T C WHR v1 0.077 0.006 (0.0035) 0.98 502 818 0.31 
v2 2.30 × 10-7 0.022 (0.0044) 0.99 259 434 0.3 
12 127094542 rs11058745 LOC100128554(dist=137211), 
LOC100996671(dist=42950) 
T C WHR adj BMI v1 0.059 0.0056 (0.0031) 0.97 502 818 0.31 
v2 4.70 × 10-7 0.02 (0.0042) 0.98 259 434 0.3 
12 127094630 rs11058746 LOC100128554(dist=137299), 
LOC100996671(dist=42862) 
T G WHR v1 0.073 0.006 (0.0034) 0.99 492 818 0.3 
v2 4.10 × 10-7 0.021 (0.0044) 0.99 254 434 0.29 
12 127094761 rs11058747 LOC100128554(dist=137430), 
LOC100996671(dist=42731) 
A C WHR v1 0.074 0.006 (0.0035) 0.99 499 818 0.31 
v2 2.40 × 10-7 0.022 (0.0044) 0.99 258 434 0.3 
12 127094761 rs11058747 LOC100128554(dist=137430), 
LOC100996671(dist=42731) 
A C WHR adj BMI v1 0.05 0.0057 (0.0031) 0.98 499 818 0.31 
v2 4.90 × 10-7 0.02 (0.0042) 0.99 258 434 0.3 
12 127094795 rs11058748 LOC100128554(dist=137464), 
LOC100996671(dist=42697) 
A G WHR v1 0.19 0.0045 (0.0037) 1 368 818 0.22 
v2 3.70 × 10-7 0.024 (0.0048) 1 193 434 0.22 
12 127094931 rs79856323 LOC100128554(dist=137600), 
LOC100996671(dist=42561) 
C A WHR v1 0.19 0.0046 (0.0037) 1 368 818 0.23 
v2 3.70 × 10-7 0.023 (0.0048) 1 193 434 0.22 
12 127095200 chr12:127095200 LOC100128554(dist=137869), 
LOC100996671(dist=42292) 
G A WHR v1 0.19 0.0045 (0.0037) 1 368 818 0.22 
v2 3.70 × 10-7 0.023 (0.0048) 1 193 434 0.22 
12 127096227 rs11058749 LOC100128554(dist=138896), 
LOC100996671(dist=41265) 
C G WHR v1 0.19 0.0046 (0.0037) 0.99 367 818 0.22 
v2 3.50 × 10-7 0.024 (0.0049) 0.99 192 434 0.22 
12 127096299 rs10847184 LOC100128554(dist=138968), 
LOC100996671(dist=41193) 
A T WHR v1 0.19 0.0046 (0.0037) 0.99 367 818 0.22 
v2 3.50 × 10-7 0.024 (0.0049) 0.99 192 434 0.22 
14 57116309 rs142932442 TMEM260 C G hip v1 1.60 × 10-7 -12 (2.6) 0.78 27 821 0.017 
v2 0.0024 -9 (3.7) 0.78 14 496 0.014 
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chr position Variant gene ref alt Trait Visit P  β (SE) info EAC N MAF 
14 97241615 rs117881117 PAPOLA(dist=208162), 
VRK1(dist=22069) 
C T BMI at max v1 2.30 × 10-7 -11 (2.8) 0.82 8 809 0.0049 
v2         
18 55589140 rs9948233 ATP8B1(dist=118813), 
NEDD4L(dist=122470) 
T C WHR females v1 2.10 × 10-7 -0.026 (0.005) 0.9 266 579 0.23 
v2 0.037 -0.011 (0.0056) 0.94 164 330 0.25 
18 55601636 rs4941202 ATP8B1(dist=131309), 
NEDD4L(dist=109974) 
T C WHR females v1 4.40 × 10-7 -0.023 (0.0046) 0.96 306 579 0.26 
v2 0.3 -0.0059 (0.0054) 0.95 175 330 0.27 
20 15619338 chr20:15619338 MACROD2 A C arm v1 1.70 × 10-7 1.6 (0.31) 1 267 824 0.16 
v2 0.089 0.76 (0.41) 1 155 497 0.16 
22 38158273 rs73168260 TRIOBP A G WHR adj BMI 
males 
v1 0.012 -0.012 (0.005) 0.98 95 239 0.2 
v2 4.20 × 10-7 -0.04 (0.0081) 0.95 44 104 0.21 
Table 7. Single Variant results for imputed data. All significant and suggestive single variant associations signals are shown in order of 
physical position. Associations are shown for both visits. The betas are all directionally consistent across visits.  
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Composite Measures of Adiposity: In addition to the analysis of traditional 
measures of obesity, associations with the composite measures of obesity, PC2 capturing 
central adiposity above or below the waist, and PC3, which captures truncal versus 
peripheral adiposity, were also analyzed. QQ and Manhattan plots are in Figures 9 and 
10; the top results are in Table 8. Multiple variants on chromosome 16 are genome-wide 
significantly associated with PC2 at the second (index SNP rs2244324, P = 2.81 × 10-8, 
N = 408, β (SE) = -0.17 (0.03), MAF= 0.30, info=0.98). There is also a suggestive 
association between PC3 at visit 2 and a variant in Down	syndrome	cell	adhesion	
molecule	(DSCAM). These were the only significant or suggestive results. 
     
    
Figure 9. QQ plots for single variant association tests with composite measures of 
adiposity.  
PC2 visit 1 PC 2 visit 2 
PC3 visit 1 PC3 visit 2 
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Figure 10. Manhattan plots for single variant association tests with composite 
measures of adiposity. 
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PC3 visit 1 PC3 visit 2 
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chr position Variant gene ref alt Trait Visit P  β (SE) info EAC N MAF 
15 31316965 rs28697571 TRPM1 G T PC2 v1 0.008 -0.13 (0.049) 0.95 59 816 0.036 
v2 4.30 × 10-7 0.34 (0.066) 0.96 36 408 0.044 
16 73832185 rs410109 LINC01568(dist=376890), 
LOC101928035(dist=394106) 
G A PC2 v1 0.69 -0.0082 (0.02) 1 474 816 0.29 
v2 1.80 × 10-7 -0.16 (0.03) 0.99 247 408 0.3 
16 73832216 rs421566 LINC01568(dist=376921), 
LOC101928035(dist=394075) 
A T PC2 v1 0.69 -0.0082 (0.02) 1 474 816 0.29 
v2 1.80 × 10-7 -0.16 (0.03) 0.99 247 408 0.3 
16 73832579 rs427478 LINC01568(dist=377284), 
LOC101928035(dist=393712) 
C T PC2 v1 0.59 -0.011 (0.02) 1 469 816 0.29 
v2 4.40 × 10-7 -0.15 (0.03) 0.99 244 408 0.3 
16 73832603 rs385183 LINC01568(dist=377308), 
LOC101928035(dist=393688) 
C A PC2 v1 0.82 -0.0048 (0.02) 0.99 483 816 0.3 
v2 1.30 × 10-7 -0.16 (0.03) 0.99 248 408 0.3 
16 73836905 rs59844697 LINC01568(dist=381610), 
LOC101928035(dist=389386) 
G T PC2 v1 1 -0.00015 (0.021) 0.99 403 816 0.25 
v2 3.10 × 10-8 -0.18 (0.031) 0.98 211 408 0.26 
16 73837290 rs328392 LINC01568(dist=381995), 
LOC101928035(dist=389001) 
C T PC2 v1 0.67 -0.009 (0.02) 0.98 477 816 0.29 
v2 2.70 × 10-7 -0.15 (0.03) 0.98 252 408 0.31 
16 73847624 rs2244324 LINC01568(dist=392329), 
LOC101928035(dist=378667) 
T A PC2 v1 0.76 0.0073 (0.02) 0.98 485 816 0.3 
v2 2.80 × 10-8 -0.17 (0.03) 0.98 246 408 0.3 
21 41463520 rs74762297 DSCAM T C PC3 v1 0.0083 0.29 (0.12) 0.87 20 816 0.012 
v2 3.60 × 10-7 -1 (0.19) 0.78 9 408 0.01 
Table 8. Single variant association tests with composite measures of adiposity. 
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Multi-trait Analysis: Using the composite measures of obesity is useful for 
capturing adiposity distribution. To capture variants effects across the spectrum of 
adiposity traits, t-test statistics were meta-analyzed across all traditional measures of 
obesity at both time points while correcting for the correlation between the test statistics 
using the software CPASSOC(175, 176). The resulting QQ and Manhattan plots are in 
Figures 11 and 12; the QQ plots show a minimal inflation in the combined test statistic. 
While no variant reached genome-wide significance, there are 9 variants in 4 loci that 
are genome-wide suggestive which are shown in Table 9. These consist of low-
frequency variants on chromosome 4, in the gene sema	domain,	immunoglobulin	
domain	(Ig),	short	basic	domain,	secreted,	(semaphorin)	3C	(SEMA3C) and in the gene 
early	B‐cell	factor	4	(EBF4), and a common variant between the genes growth	arrest‐
specific	7 (GAS7) and myosin,	heavy	chain	13,	skeletal	muscle	(MYH13). The 
association between these variants and traditional measures of obesity are all sub-
significant. The most convincing of these signals is the variant between GAS7 and 






Figure 12. Manhattan plot of single variant multi-trait analysis.  
chrom position Variant Gene ref alt P-value MAF 
4 182524751 chr4:182524751:D LINC00290(dist=444449), 
LOC90768(dist=535062) 
TA T 4.55 × 10-7 0.0098 
7 80503452 rs58283863 SEMA3C A G 3.29 × 10-7 0.0049 
17 10105523 rs77233190 GAS7(dist=3655), 
MYH13(dist=98660) 
A G 3.42 × 10-7 0.2488 
20 2688091 rs79712868 EBF4 C T 6.91 × 10-8 0.0165 
20 2691964 rs8121831 EBF4 A G 1.17 × 10-7 0.0170 
20 2696131 rs80151839 EBF4 G A 1.18 × 10-7 0.0170 
20 2699607 rs80023036 EBF4 A G 1.37 × 10-7 0.0173 
20 2705316 rs79049619 EBF4 C T 1.34 × 10-7 0.0171 
20 2705474 rs112916871 EBF4 C T 1.34 × 10-7 0.0171 
Table 9. Multi-trait single variant analysis top results.  
Gene based Associations: The QQ plots for the gene-based test VEGAS are 
systematically deflated, with genomic inflation factors ranging from 0.94 to 0.99. In the 
QQ plots (Figure 13) there are small shelves instead of a smooth linear line. This reflects 
rounding, as the number of simulations performed with in the VEGAS association test is 
increased only if required to establish significance. In addition to this, deflation reflects 
limited power due to sample size. 
Using a genome-wide significance cut off of p < 2.5 × 10-6, which is the 
equivalent of correcting for the approximately 20,000 genes in the human genome, one 
Multi‐trait	Analysis 
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gene across all the traits is genome-wide significant. C8orf4 is associated with BMI at 
maximum weight. Looking down an order of magnitude to 2.5 × 10-5, an additional 15 
loci (16 genes) are associated with at least one trait, as shown in Table 10. This includes 
both Oxidized Low Density Lipoprotein (Lectin-Like) Receptor 1 (OLR1) and 
transmembrane protein 52B (TMEM52B) on chromosome 12 which are associated with 
multiple waist to hip ratio outcomes at visit 1. These two gene-based tests are 
overlapping with each other. Similarly, two transcripts associated with percent body fat 
at visit 2, ring finger protein 13 (RNF13) and LOC100422259, represent also 
overlapping regions on chromosome 3.  
Gene-based Associations of Composite Measures: In addition to looking at the 
traditional measures of obesity, we also tested for association between transcripts and the 
composite measures of adiposity, PC2, which captures adiposity above or below the 
waist, and PC3, which captures central versus peripheral adiposity. Only three 
transcripts are suggestively associated with PC3 at visit 1 (Figures 15 and 16, Table 11). 
Two of the transcripts are physically overlapping and both represent portions of the T 
cell receptor alpha variable region (TRAV12-3 and TRAV8-6). 
Figure 13. QQ plots for common variant gene-based association tests. 55	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Visit 1 Visit 2 
Trait Name Chr Start End Length SNPs Tests Pval SNPs Tests Pval 
WHR adj BMI males ECE1 1 21543740 21672034 128295 531 29.3 0.0014 433 21.0 1.52 × 10-5 
percent body fat RNF13 3 149530475 149679926 149452 405 30.7 0.040 407 28.8 4.00 × 10-6 
percent body fat LOC100422259 3 149656780 149657584 805 66 14.3 0.059 66 13.9 1.20 × 10-5 
WHR males LOC100420939 3 172398504 172399011 508 136 12.6 2.34 × 10-5 109 7.9 0.0013 
WHR adj BMI females RPL9P16 4 169676949 169677632 684 140 11.6 2.30 × 10-5 140 11.6 0.20 
WHR females RPL9P16 4 169676949 169677632 684 140 11.6 2.40 × 10-5 140 11.6 0.119 
arm C4orf27 4 170650619 170679093 28475 160 18.7 0.021 146 19.5 1.80 × 10-5 
arm LOC642554 6 64151128 64153818 2691 112 11.2 0.0089 111 10.1 2.02 × 10-5 
WHR adj BMI males COPS5P 6 93801543 93802701 1159 108 17.2 0.84 92 10.1 9.69 × 10-6 
BMI at max C8orf4 8 40010989 40012821 1833 114 22.5 2.00 × 10-6       
WHR PGM2L1 11 74041361 74109502 68142 322 24.2 0.14 325 25.6 2.41 × 10-5 
WHR adj BMI females OLR1 12 10310899 10324790 13892 228 19.2 1.72 × 10-5 228 20.2 0.75 
WHR OLR1 12 10310899 10324790 13892 226 20.3 2.27 × 10-5 230 19.3 0.49 
WHR females OLR1 12 10310899 10324790 13892 228 19.2 4.00 × 10-6 228 20.2 0.82 
WHR TMEM52B 12 10331557 10344403 12847 252 19.9 3.00 × 10-6 258 19.2 0.168 
WHR females TMEM52B 12 10331557 10344403 12847 255 19.3 3.00 × 10-6 257 19.7 0.54 
WHR adj BMI males RPL19P17 12 12721058 12721732 675 84 16.1 0.25 80 14.1 1.81 × 10-5 
arm LOC401767 14 25894117 25901442 7326 261 26.4 0.021 249 23.9 1.71 × 10-5 
waist PFDN4 20 52824502 52836492 11991 276 22.6 2.01 × 10-5 247 22.2 0.43 
WHR adj BMI males PLA2G3 22 31530793 31536469 5677 116 19.1 0.59 99 13.5 3.00 × 10-6 
Table 10. Common variant gene-based association results.  
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Visit 1 Visit 2 
Trait Name Chr Start End Length SNPs Tests Pval SNPs Tests Pval 
PC3 MYCL1 1 40361096 40367687 6592 130 13.6 1.49 × 10-5 131 14.6 0.089 
PC3 TRAV12-3 14 22433736 22434290 555 199 13.4 1.96 × 10-5 200 13.7 0.0071 
PC3 TRAV8-6 14 22446919 22447360 442 157 10.7 2.22 × 10-5 158 11.2 0.0090 
Table 11. VEGAS association results for composite adiposity measures.
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Multi-trait Gene-Based analysis: As with the single variant analyses, a multi-trait 
analysis was conducted for the gene-based results generated by VEGAS (Figures 17 and 
18). Three transcripts come up as genome-wide significant or suggestive and are shown 
in Table 12. All three are located on chromosome 17p13.2 and are physically adjacent or 
overlapping. While no variant in these genes or the genes themselves came up as 
significant or suggestive for any one trait, the most significant gene-based signal is an 
association between Germ Cell Associated 2 (GSG2) and WHR adjusted for BMI at the 
first visit (p = 3.75 × 10-5). For these three transcripts, multiple traits were nominally 
associated with these three genes including BMI, arm circumference, hip circumference, 
and percent body fat at visit 2, BMI at maximum, WHR with and without adjusting for 
BMI and hip circumference at visit 1, indicating these genes have a small impact on 
multiple traits. 
	
Figure 17. Multi-trait common variant gene-based analysis QQ plot. 
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Figure 18. Multi-trait common variant gene-based analysis Manhattan plot 
chr gene start end p-value 
17 P2RX5-TAX1BP3 3566187 3599698 1.66 × 10-5 
17 P2RX5 3576521 3599698 1.46 × 10-5 
17 GSG2 3627197 3629993 9.02 × 10-7 
Table 12. Multi-trait common variant gene-based analysis top associations  
DISCUSSION 
Based on the sexual dimorphism, WHR residuals were created within sex 
stratum. Genetic analyses were performed both in the combined residuals and separately 
for males and females. Based on the top association signals shown in Table 7, there is of 
overlap of association signals between the female and sex-combined analyses, this is not 
apparent with males. This is due to the much lower male sample size resulting from the 
sample being about 75% female. The composite measures, PC2 is also sexually 
dimorphic, however in this case the residuals were highly correlated whether samples 
were stratified on sex or sex was adjusted for as a covariate. Genetic analyses of PC2 
were done on the residuals created using sex as a covariate. 
Due to the correlation between BMI and WHR, WHR analyses were done both 
with and without a BMI covariate. By including BMI as a covariate, the GIANT 
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consortium has successful identified loci that are associated with central adiposity, and 
not overall BMI(107). Despite the success of this approach in large consortium settings, 
in these data the correlation between associations with and without BMI were high 
(r2>0.8), and most signals were stronger in the analysis without adjusting for BMI. 
However there are some signals that are stronger after adjusting out BMI, but only 
rs74862838 on chromosome 1 reached genome-wide suggestive criteria. 
The analysis of the same adiposity traits measured in the same people 8.5 years 
apart should yield highly correlated results. However many of the top signals in Table 7 
are not associated or are only associated at a nominal level for the other time point. The 
raw traits are correlated across the visits with an r2 ranging from 0.72 to 0.90 (see Table 
3 in chapter 2). The t-statistics are much less correlated (r2 ranging from 0.03 to 0.94, 
excluding WHR adjusted for BMI); this is primarily due to including a non-random 
subset of samples from the first visit in the second visit and secondarily due to changes 
in BMI over time. While there was some loss to follow up, most individuals were 
excluded from the analysis due to being treated for type 2 diabetes prior to the second 
visit. Because these samples are not missing at random, the different associations may be 
due to differences in adiposity between those that did not develop diabetes over the 8.5 
years between visits and those that did. The individuals that develop diabetes within a 
short time frame are the most interesting, because this is time frame in which disease 
development may be preventable with targeted intervention. 
Despite having very few significant and suggestive signals, some of these signals 
are biologically interesting. To start with, variants in the same region as some 
associations reported here have previously been associated with obesity related traits. 
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These include variants in and near NPY, PKHD1, and MACROD2. NPY encodes 
neuropeptide Y, a signaling molecule that acts in the nervous system, including in the 
arcuate nucleus of hypothalamus, regulating hunger and satiety along side POMC and 
the leptin-melanocortin pathway(178). In Starr County, previous linkage studies have 
associated this gene with obesity(30). Here we report an association of a rare variant 
(MAF = 0.6%) 200kb from NPY with BMI at the first visit; this association is not seen at 
the second visit due to having fewer than 5 carriers.  
PKHD1, which when mutated can cause autosomal recessive polycystic kidney 
disease(179), has previously been associated with waist circumference(101) and weight 
loss following bariatric surgery(180). Our associated variant PKHD1 has a much lower 
MAF, indicating it is not in strong LD with previously reported signals. The initial 
association with smaller WHR adjusted for BMI at the first visit is diminished at visit 2, 
despite only having one fewer carrier. The imputation quality is at the lower boundary 
(info = 0.7) of variants that we examined, calling the association observed here into 
doubt.  
MACROD2 was previously reported as associated with disordered eating(181) 
and suggestively associated with extreme obesity(94). The protein is expressed in many 
tissues including the brain, liver, muscle and pancreas(182). Our reported suggestive 
association with arm circumference further supports previous findings that this region of 
the genome plays a role in obesity. 
Beyond these previously reported loci, there are also additional biologically 
interesting loci. GABRB2, encodes a subunit of gamma-aminobutyric acid (GABA) A 
receptor, which mediates inhibitory synaptic signal transmission in the nervous 
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system(183). The GABAA receptor is composed of five subunits, usually two alpha class 
subunits, two beta class subunits, and one gamma class subunit(184). The various 
homologs of each subunit class have different specificities to allosteric modulators 
including many pharmacological agents including benzodiazepines(184). The GABAA 
receptor is largely responsible for inhibitory signals to the hypothalamo–pituitary–
adrenocortical axis(185). Dysregulation of this signaling pathway, as occurs under stress, 
is related to obesity(186, 187). Genes encoding other subunits of the receptor have 
previously been associated with obesity related traits including GABRB1 with change in 
weight in Hispanic children(188) and GABRA4 with type 2 diabetes(189). We reported 
an association of a rare variant in GABRB2 with WHR at the second visit. This variant is 
imputed, however the quality at the second visit is near the minimum threshold for 
inclusion.  
Carriers of the rare allele of rs112863316 in LPIN1 had an average of 8.6% 
higher percent body fat than non-carriers at the first visit. There are far fewer carriers at 
the second visit (21 at visit 1 compared to 11 at visit 2) reducing power to detect an 
effect. Mice harboring knock out mutations in this gene have characteristics typical of 
human lipodystrophy, including neonatal fatty liver, hypertriglyceridemia in infancy, 
adipose tissue deficiency, and glucose intolerance(190). Overexpression of Lpin1 in 
adipose tissue results in mice with diet-induced obesity and enhanced insulin 
sensitivity(191). This suggests a causal variant in the region may increase LPIN1 
expression or activity.  
These handful of associations are biologically interesting candidates. While 
biological plausibility gives us confidence in an association results, it is neither 
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necessary nor sufficient to conclude a variant or gene is causative. Replication in 
independent studies is needed to determine if these variants truly play a role in fat 
distribution, or if these associations are spurious. These regions have not previously been 
associated with obesity related traits, however large-scale studies including very rare 
variants are still underway. 
Most of these variants are low frequency, resulting in lower imputation quality. 
While strict quality control criteria were applied, imputation leaves additional 
uncertainty in the genotypes. If one of ten individuals called as a carrier were incorrectly 
imputed, then the test statistic could be drastically altered. Using sequencing data, or 
arrays intended to capture rare variation will give us additional certainty in the 
genotyping. 
The multi-trait analysis will detect associations in multiple traits that are not due 
to the correlation across the traits. For this analysis, only four signals are suggestive 
(Table 9). Zhu et al. propose an extension that allows for heterogeneous effects across 
traits and studies, however the original method is more powerful when considering traits 
on the same scale(176). Since we are analyzing inverse normalized residuals, the 
original method was utilized. Two of the suggestive results are biologically interesting. 
rs7723319 resides between GAS7 and MYH13. MYH13 encodes a part of the myosin 
heavy chain, which is a key part of skeletal muscle fibers. GAS7 encodes growth arrest-
specific 7, which plays a role in neuronal development. Multiple low-frequency variants 
in EBF4, which encodes early B cell factor 4, are suggestively associated with these 
traits. EBF4 plays a role in both neuronal development and B-cell maturation. Because 
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we know neuronal signaling and development are important for hunger and satiety, both 
of these genes are biologically plausible.  
 While gene-based analyses offer the potential to identify genes that contain 
multiple smaller effect size variants, the association results from VEGAS, using genes 
and 20 kilobases in each direction, yielded only one genome-wide significant result, in 
28 different analyses. While the lack of signal may be due to not having genes with 
multiple variants independently associated with obesity-related traits, it could also be 
due to a number of considerations for gene-based tests. Including 20 kilobases in both 
directions from the gene may include many null variants, diminishing the combined 
signal. To check this, a secondary analysis was run including only three kilobases in 
each direction from genes. This analysis was also well calibrated, however it did not 
reveal stronger signal. Each window size identified some unique associations, however 
most signals were common to both analyses. Another option to alleviate the problem of 
excessive null signal is to include only variants that are associated at some preset level. 
This requires additional statistical considerations to account for the bias. To decrease the 
number of variants we can also use functional annotation to include only variants we 
have biological reason to think could impact protein function. Genome-wide array data 
has little coding variation well represented, and annotation informed approaches are 
better suited to coding-centric data, as will be investigated in chapter 4. 
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Chapter 4: Whole Exome Sequencing 
INTRODUCTION 
While genome-wide arrays, offer an agnostic look across the genome, it is often 
difficult to parse out causative transcripts and variants from these data. They do not 
provide sufficient coverage of the mutations and variants that are most likely to be 
functional. When trying to assess functionality of a variant, the most clear cut case is that 
of a protein altering variant, that is one that changes the amino acid sequence, length, or 
splicing of the gene product. Very few protein-altering variants are assayed on genome-
wide chips. Some coding variants are imputed, but these are limited to common 
haplotypes that are represented in the 1000 genomes reference panel. The development 
of next generation sequencing, however, provides the opportunity to interrogate most of 
coding variation either through whole genome or whole exome sequencing. 
While the “thrifty gene” hypothesis would support the idea that genetic variants 
increasing efficiency of energy storage would be common(20), this applies to older 
variation that has undergone generations of selection during times of famine. The Exome 
Sequencing Project (ESP), has shown us that while most variation within a data set is 
rare (86% of variants have a MAF<0.5%), most of an individual’s variation is 
common(192). At the study level, ESP reported 58% of variants in whole exome 
sequencing data are nonsynonymous and 38% are synonymous, while individuals 
average 35 nonsense variants, 5754 missense variants, and 7652 synonymous 
variants(192). A considerable amount of the variation passed down from parent to 
offspring is rare and relatively recent variation and consequently it has not had sufficient 
time for selection to play its role. Both common variants that may have been selected for 
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when famine was a selective pressure, and more recent rare variation are shared and 
plausibly contribute to the genetic architecture of obesity.  
To assess the role of coding variation in obesity, unrelated individuals with 
genome-wide array data were whole exome sequenced, although a subset were removed 
prior to sequencing due to insufficient DNA. More common variants were tested for 
associations with the same traditional measures of adiposity as in chapter 3, as well as 
the composite measures of adiposity derived in chapter 2. To assess the role of low 
frequency and rare variants, gene-based tests aggregating variants across a transcript 
were used for the same outcomes. As in chapter 3, the test statistics from the traditional 
adiposity measures were meta-analyzed correcting for the correlation between traits, to 
identify genes independently associated with multiple obesity measures. 
METHODS 
 Whole Exome Sequencing: The T2D-GENES Consortium was formed to 
investigate the role of coding variation in type 2 diabetes across multiple ancestry 
groups. As part of this consortium, 13,000 individuals from 5 ancestry groups were 
whole exome sequenced, including all of the 1618 unrelated Starr County samples with 
Affymetrix 6.0 genotype data available that were analyzed in chapter 3. Sequencing was 
performed using Agilent SureSelect All Exon Kit v.2. Using Picard 
(http://picard.sourceforge.net), sequencing reads were processed and aligned to hg19 
reference genome. The GATK HaplotypeCaller was used to call variant sites across 26k 
samples that represent the T2D-GENES consortium as well as SIGMA LuCamp, and the 
Exome Sequencing Project (193). A total of 1,497 unrelated Starr County samples were 
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successfully sequenced; however 7 failed QC metrics such as excess heterozygosity, 
excess non-reference alleles, or low GWAS concordance.	
Single variant analysis: Tests of association with each variant with a minor allele 
count of at least five were performed using a linear regression model accounting for 
cryptic relatedness between individuals using EMMAX as implemented in the EPACTS 
pipeline(194). Variants with a minor allele count of less than five were excluded due to 
instability in model for very rare variants. To adjust for population structure two genetic 
principal components, as described in chapter 3, were included as covariates. Exome-
wide significance was defined as P < 5 × 10-7, which corrects for the approximately 
100,000 coding variants tested. Variants with P < 5 × 10-6 were considered exome-wide 
suggestive. 
Gene grouping criteria: All variants were annotated using SnpEff v.3.1 and 
dbNSFP(195-197). Annotation provides information about the impact of a variant on 
each gene-product. For gene-based testing, variants were annotated to all possible 
transcripts and variants within each transcript were included based on these annotations 
and the minor allele frequency in the Starr County data. Transcript specific annotations 
were used instead of most deleterious annotation in the gene, because alternative 
transcripts are found in different amounts across various tissues, making them the logical 
biological product of interest. Criteria, number of transcripts and number of variants 












      “PTV” 
stop loss, stop gained, 
initiator codon, splice 
acceptor, splice donor, 
frame shift 




       “LR” 
Truncating variants and 
splice region, missense, 
miRNA, in frame mutations 
predicted damaging by 
metaLR(198) 
1% 31,379 19,140 
Protein altering  
 
       “NS” 
Truncating variants and 
splice region, missense, 
miRNA, in frame 
1% 195,132 74,124 
Table 13. Criteria for gene-based grouping.  Variants were annotated to all possible 
transcripts using SnpEff(195).  
Gene based association testing: For rare and low frequency variants, single 
variant test are underpowered and sometimes unstable. To test for an association across a 
transcript, variants annotated to with functional impacts as described in Table 13 were 
aggregated together using SKAT-O, as implemented in EPACTS, including a linear 
mixed model to account for cryptic relatedness (194, 199). SKAT-O optimizes between 
SKAT, which allows variants to have different directions of effect, and traditional 
burden test, which assumes that all variants have the same direction of effect(199).  
Multi-trait analysis 
Assessment of overall significance across the array of obesity related measures 
was conducted by combining the t-statistics across traits adjusting for the correlation 
between traits. Analysis was conducted using the software CPASSOC(175, 176). For 
gene-based tests, p-values were transformed into a multivariate normal distribution by 
applying the inverse of the normal cumulative probability function. These values were 
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than combined across traits accounting for the correlation across traits, as for single 
variants. The gene-based p-values of the resulting test statistic were calculated from the 
Gamma distribution, due to inflated type I error in simulated data sets when using the 
originally proposed Chi-squared distribution (Hao Hu personal communication, January 
2, 2015).  
RESULTS 
Single variant associations: The single variant test statistics are well calibrated, 
meaning they follow the expected null distribution, after quality control. QQ and 
Manhattan plots for all 24 traditional adiposity measurements are in Figures 19 and 20, 
respectively. The genomic inflation factors (λ) range from 0.995 to 1.017, indicating that 
there is not systematic inflation of the test statistic and any population structure is 
sufficiently controlled for.  
Variants that are significantly (P < 5 × 10-7) or suggestively (P < 5 × 10-6) 
associated with any of these 24 obesity related traits are in Table 13. A total of 3 
significant associations at 3 loci were observed. A common synonymous variant 
(rs5996200, p = 2.52 × 10-8, β (SE) = 2.2 (0.37), MAF= 0.11) in CYB5R3 was 
significantly associated with arm circumference at visit 1, and also suggestively 
associated with arm circumference at visit 2 and BMI at visit 1. A common intronic 
variant (rs2301922, p = 2.71 × 10-7, β (SE) = 4.2 (0.87), MAF= 0.24) in WIPF3 is 
associated with waist circumference at visit 1; the same variant is also suggestively 
associated with BMI at visit 1. Lastly, a low-frequency synonymous variant 
(rs117042905, p = 2.41 × 10-7, β (SE) = -0.083 (0.8018, MAF= 0.03) in ARHGAP39 is 
associated with WHR adjusted for BMI in males at visit 2; this is based on 89 men. 
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chr pos variant gene ref alt protein change consequence trait visit P  β (SE) EAC N MAF 
3 141905253 rs9837628 GK5 C A NA intronic WHR females
v1 1.97 × 10-6 -0.025(0.0055) 152 515 0.14757 
v2 0.09073 -0.011(0.0068) 86 292 0.14726 





v1 3.86 × 10-6 -0.023(0.0050) 152 516 0.14729 
v2 0.1219 -0.0099(0.0067) 86 291 0.14777 
3 141905259 rs9857725 GK5 T G NA intronic WHR females
v1 1.46 × 10-6 -0.026(0.0055) 152 516 0.14729 
v2 0.1121 -0.010(0.0069) 86 291 0.14777 
3 141905261 rs9857726 GK5 T G NA intronic WHR females
v1 2.18 × 10-6 -0.025(0.0055) 152 516 0.14729 
v2 0.1056 -0.010(0.0068) 86 292 0.14726 
5 161116672 rs3811993 GABRA6 C T T187M missense WHR 
v1 0.3015 -0.013(0.015) 16 755 0.0106 
v2 3.48 × 10-6 -0.090(0.019) 10 395 0.01266 
6 46684222 rs1805017 PLA2G7 C T R92H missense WHR males 
v1 0.1453 -0.0098(0.0065) 136 216 0.31481 
v2 3.81 × 10-6 -0.044(0.0094) 55 89 0.30899 









v1 2.92 × 10-6 0.023(0.0047) 50 196 0.12755 
v2 0.01222 0.023(0.0081) 22 79 0.13924 





v1 2.81 × 10-6 -0.063(0.014) 19 539 0.01763 
v2 0.02583 -0.033(0.016) 16 306 0.02614 





v1 2.81 × 10-6 -0.063(0.014) 19 539 0.01763 
v2 0.02583 -0.033(0.016) 16 306 0.02614 





v1 2.81 × 10-6 -0.063(0.014) 19 539 0.01763 
v2 0.02583 -0.033(0.016) 16 306 0.02614 
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chr pos variant gene ref alt protein change consequence trait visit P  β (SE) EAC N MAF 
7 29915593 rs2301922 WIPF3 G C NA intronic BMI 
v1 6.01 × 10-7 1.8(0.37) 363 762 0.23819 
v2 0.002171 1.5(0.54) 190 399 0.2381 
7 29915593 rs2301922 WIPF3 G C NA intronic waist 
v1 2.71 × 10-7 4.2(0.87) 361 759 0.23781 
v2 0.003174 2.8(1.1) 217 455 0.23846 





v1 0.005126 -0.028(0.0098) 22 216 0.05093 
v2 2.41 × 10-7 -0.083(0.018) 6 89 0.03371 
12 10313075 rs3736235 OLR1 T C NA intronic WHR females
v1 4.01 × 10-6 0.020(0.0040) 543 537 0.49441 
v2 0.7703 -0.0019(0.0052) 289 305 0.47377 
22 40803186 rs2018393 SGSM3 G T NA intronic BMI 
v1 1.82 × 10-6 -1.5(0.33) 982 760 0.35395 
v2 0.002968 -1.3(0.48) 513 398 0.35553 
22 42998902 rs113513063 POLDIP3 G T P108P synonymous BMI 
v1 1.39 × 10-6 8.6(1.5) 16 762 0.0105 
v2 0.0006665 8.0(2.1) 10 399 0.01253 




v1 2.32 × 10-6 0.092(0.021) 16 761 0.01051 
v2 0.001145 0.078(0.026) 10 372 0.01344 
22 43032742 rs5996200 CYB5R3 C T P77P synonymous BMI 
v1 9.41 × 10-7 2.6(0.50) 170 762 0.11155 
v2 0.00119 2.5(0.74) 90 399 0.11278 
22 43032742 rs5996200 CYB5R3 C T P77P synonymous arm 
v1 2.52 × 10-8 2.2(0.37) 169 761 0.11104 
v2 1.15 × 10-5 2.2(0.49) 102 455 0.11209 
Table 14. Significant and suggestive single variant associations from exome sequencing. 
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 Composite adiposity measures: In addition to traditional measures of adiposity, 
associations with the composite measures of adiposity, PC2 and PC3, which capture 
truncal adiposity above or below the waist, and central versus peripheral adiposity 
respectively, were also tested. The QQ and Manhattan plots are in Figures 21 and 22, 
respectively. There were only two suggestive associations, as shown in Table 15. The 
association with PC2 at visit 1 in TRAK1 (rs4234445, p = 2.12 × 10-6, β (SE) = 
0.12(0.025), MAF= 0.19) replicates a prior suggestive association with visceral adipose 
tissue/subcutaneous adipose tissue ratio(200).  
Figure 21. QQ plots for exome sequencing single variant association tests with 
composite measures of adiposity.  
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Figure	  22.	  Manhattan	  plots	  for	  exome	  sequencing	  single	  variant	  association	  
tests	  with	  composite	  measures	  of	  adiposity.
PC2 visit 1 PC 2 visit 2 
PC3 visit 1 PC3 visit 2 
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chr pos variant gene ref alt protein change consequence trait visit P  β (SE) EAC N MAF 
3 42226151 rs4234445 TRAK1 T C NA intronic PC2 
v1 2.12 × 10-6 0.12(0.025) 1218 753 0.19124 
v2 0.1475 -0.052(0.037) 586 370 0.20811 
21 41465622 rs78085341 DSCAM A T NA intronic PC3 
v1 0.003124 0.33(0.12) 17 753 0.01129 
v2 1.26 × 10-6 -0.82(0.16) 9 370 0.01216 
Table 15. Significant and suggestive single variant associations with composite adiposity measures from exome sequencing. 
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Multi-trait analysis: In addition to analyzing composite measures of obesity (PC2 
and PC3), analysis was conducted combining the t-test statistics across adiposity trait 
while accounting for correlation using the software CPASSOC(175, 176). QQ and 
Manhattan plots are in Figures 23 and 24 respectively. The test statistic was well 
calibrated with a genomic inflation factor of 1.002. Significantly and suggestively 
associated variants are in Table 17. Only rs57772251 was the only variant to reach 
exome-wide significant (p = 2.34 × 10-7, MAF=0.001). All significant and suggestive 
signals were intronic. 
	
Figure 23. Multi-trait analysis QQ plot of single variant exome sequencing variants.  
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Figure 24. Multi-trait analysis Manhattan plot of single variant exome sequencing 
variants.  
chr position variant ref alt gene function MAF p-value 
2 33810799 var_2_33810799 A G FAM98A INTRONIC 0.007 2.63 × 10-6 
5 147812971 rs147707335 T C FBXO38 INTRONIC 0.012 4.16 × 10-6 
11 64594490 rs57772251 A G CDC42BPG INTRONIC 0.001 2.34 × 10-7 
16 2161887 var_16_2161887 C T PKD1 INTRONIC; 
CREATE SPLICE 
ACCEPTOR 
0.0054 2.42 × 10-6 
Table 16. Significant and suggestive associations from multi-trait analysis of single 
variant exome sequencing variants.  
Gene-based associations: The QQ plots for gene-based SKAT-O tests for 
traditional measures of adiposity are in Figure 25, and exhibit some shelves or plateaus, 
reflecting genes with multiple transcripts, that result in redundant test statistics. For the 
three different grouping criteria defined in Table 13 as protein truncating with a MAF < 
5% (PTV), PTV plus protein altering predicted damaging with a MAF < 1% (LR), PTV 
plus protein altering with a MAF < 1% (NS), the test statistics were generally well 
calibrated, although genomic inflation factors range from 0.82 to 1.1. The small genomic 
inflation factors reflect phenotypes with small sample sizes, as low as 89 for male 
 90	
specific analyses at visit 2, as well as the small number of tests in comparison to single 
variant tests. The large genomic inflation factors show early departure from the expected 
distribution, in part due to the redundancy of including multiple transcripts.  
The Manhattan plots for the gene-base SKAT-O tests are in Figure 26. There 
were no exome-wide significant results (p < 2.5	× 10-6) for any variant grouping or trait. 
Ten suggestive associations (p < 2.5 × 10-5) with nine genes are in Table 17. Results for 
both time points and each of the three masks are included. In the case where multiple 
transcripts were redundant, only the transcript with the smallest p-value was included in 
the table. Eleven of the associations come from the NS mask, which contains low 
frequency protein altering variants regardless of functional prediction; all but three of 
these genes include fewer than two variants in the other masks.  
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Figure	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Figure	  26.	  Manhattan	  plots	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  gene-­‐based	  association	  tests.	  	  Associations	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  each	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  masks	  are	  shown.	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  truncating	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  predicted	  damaging	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  and	  NS-­‐	  PTV	  mask	  plus	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  variants	  with	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Figure	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  plots	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  gene-­‐based	  association	  tests.	  	  Associations	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  each	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  masks	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  shown.	  PTV-­‐	  protein	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  mask	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  gene-­‐based	  association	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            visit 1 visit 2 
trait chr start end transcript gene mask P-value # variants cMAF P-value # variants cMAF 
WHR 1 3412521 3527764 ENST00000485002 MEGF6 PTV 0.25058 1 0.0079 0.0078885 1 0.0076 
LR 0.052417 6 0.0331 0.012905 4 0.0203 
NS 6.99 × 10-6 27 0.0808 0.00071479 19 0.0734 
hip 2 108910275 108924881 ENST00000251481 SULT1C2 PTV 5.00 × 10-6 2 0.0092 0.0082261 1 0.0066 
LR 1.30 × 10-5 3 0.0092 0.0020738 2 0.0066 
NS 0.0017541 9 0.0369 0.047537 7 0.0374 
hip 3 112647783 112693652 ENST00000295863 CD200R1 PTV NA NA NA NA NA NA 
LR NA NA NA NA NA NA 
NS 1.41 × 10-5 4 0.0119 0.0045153 4 0.0110 
arm 3 124114153 124165606 ENST00000393501 KALRN PTV 0.52068 1 0.0013 0.16982 1 0.0022 
LR 0.52068 1 0.00131 0.16982 1 0.0022 
NS 0.19228 3 0.0092 4.11 × 10-6 3 0.0109 
percent 
body fat 
3 124114153 124165606 ENST00000393501 KALRN PTV 0.52528 1 0.0013 0.091004 1 0.0027 
LR 0.52528 1 0.0013 0.091004 1 0.0027 




3 142443450 142524981 ENST00000476941 TRPC1 PTV NA NA NA NA NA NA 
LR NA NA NA NA NA NA 
NS 1.59 × 10-5 6 0.0159 0.25612 4 0.0203 
BMI at 
18 
16 78056542 78064574 ENST00000575655 CLEC3A PTV NA NA NA     
LR NA NA NA     
NS 7.04 × 10-6 3 0.0053     
waist 17 25621468 25633916 ENST00000581185 WSB1 PTV NA NA NA NA NA NA 
LR 0.46123 2 0.0026 NA 0 NA 
NS 6.97 × 10-6 5 0.0119 9.95 × 10-5 2 0.0087912 
waist 20 44511257 44512293 ENST00000372520 ZSWIM1 PTV 0.000015736 1 0.0369 0.032595 1 0.0373 
LR 0.000015736 1 0.0369 0.032595 1 0.0373 
NS 1.55 × 10-5 3 0.0408 0.034529 3 0.0418 
Table 17. Suggestive gene-based associations with traditional obesity measures.  
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Composite adiposity measures: In addition to looking at the traditional measures 
of obesity, we also tested for association between transcripts and the composite measures 
of adiposity, PC2, which captures adiposity above or below the waist, and PC3, which 
captures central versus peripheral adiposity. Three genes are suggestively associated 
with these composite measures (Figures 27 and 28, Table 18). This includes an 
association with Long chain acyl-CoA synthetase 1 (ACSL1) with PC3 at the first visit. 
At the second visit the association persists but is slightly weaker.  
  
Figure	  27.	  QQ	  plots	  for	  gene-­‐based	  association	  tests	  with	  composite	  
measures	  of	  obesity.	  	  Associations	  for	  each	  of	  three	  masks	  are	  shown.	  PTV-­‐	  protein	  truncating	  variants	  with	  MAF	  <	  5%,	  LR-­‐	  PTV	  mask	  plus	  nonsynonymous	  variants	  with	  MAF	  <	  1%.	  predicted	  damaging	  by	  metaLR,	  and	  NS-­‐	  PTV	  mask	  plus	  nonsynonymous	  variants	  with	  MAF	  <	  1%.	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Figure	  27.	  QQ	  plots	  for	  gene-­‐based	  association	  tests	  with	  composite	  
measures	  of	  obesity.	  	  Associations	  for	  each	  of	  three	  masks	  are	  shown.	  PTV-­‐	  protein	  truncating	  variants	  with	  MAF	  <	  5%,	  LR-­‐	  PTV	  mask	  plus	  nonsynonymous	  variants	  with	  MAF	  <	  1%.	  predicted	  damaging	  by	  metaLR,	  and	  NS-­‐	  PTV	  mask	  plus	  nonsynonymous	  variants	  with	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Figure	  28.	  Manhattan	  plots	  for	  gene-­‐based	  association	  tests	  with	  composite	  
measures	  of	  obesity.	  	  Associations	  for	  each	  of	  three	  masks	  are	  shown.	  PTV-­‐	  protein	  truncating	  variants	  with	  MAF	  <	  5%,	  LR-­‐	  PTV	  mask	  plus	  nonsynonymous	  variants	  with	  MAF	  <	  1%.	  predicted	  damaging	  by	  metaLR,	  and	  NS-­‐	  PTV	  mask	  plus	  nonsynonymous	  variants	  with	  MAF	  <	  1%.	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Figure	  28.	  Manhattan	  plots	  for	  gene-­‐based	  association	  tests	  with	  composite	  
measures	  of	  obesity.	  	  Associations	  for	  each	  of	  three	  masks	  are	  shown.	  PTV-­‐	  protein	  truncating	  variants	  with	  MAF	  <	  5%,	  LR-­‐	  PTV	  mask	  plus	  nonsynonymous	  variants	  with	  MAF	  <	  1%.	  predicted	  damaging	  by	  metaLR,	  and	  NS-­‐	  PTV	  mask	  plus	  nonsynonymous	  variants	  with	  MAF	  <	  1%.	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            visit 1 visit 2 
trait chr start end transcript gene mask P-value # variants cMAF P-value # variants cMAF 
PC3 4 185678318 185678403 ENST00000503407 ACSL1 PTV NA NA NA NA NA NA 
LR NA NA NA NA NA NA 
NS 2.42 × 10-5 3 0.0053 6.3 × 10-5 2 0.0081 
PC3 6 10874532 10877397 ENST00000379491 GCM2 PTV NA NA NA NA NA NA 
LR 0.00328 1 0.0027 0.00444 1 0.0027 
NS 5.88 × 10-6 7 0.0425 0.000885 5 0.0432 
PC2 14 24675130 24677343 ENST00000428351 TSSK4 PTV 0.00198 2 0.0106 0.608 2 0.0135 
LR 0.00198 2 0.0106 0.608 2 0.0135 
NS 9.21 × 10-6 5 0.0186 0.0924 5 0.0216 
Table 18. Suggestive gene-based associations with composite adiposity measures. 
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Gene-based multi-trait analysis: As with single variant analyses, transcripts were 
analyzed across the array of obesity related traits. The test statistics were well calibrated 
to a Gamma distribution as shown in the QQ plots in Figure 29; the corresponding 
Manhattan plots are in Figure 30. Three transcripts in the NS variant grouping attained 
exome-wide suggestive criteria (p < 2.5 × 10-5) (Table 19). None of these transcripts 
were strongly associated with anyone one trait. Both DLG4 and INPP5F are driven by 
many traits with weak associations. In contrast, RUNX3 is nominally associated with 
only 3 traits, BMI and arm circumference at visit 2 and hip circumference at visit 1. 
chr start end transcript gene P-value 
1 25254224 25256161 ENST00000308873 RUNX3 6.99 × 10-6 
10 121551155 121556996 ENST00000369083 INPP5F 2.42 × 10-5 
17 7107367 7107559 ENST00000447163 DLG4 5.41 × 10-6  
Table 19. Suggestive gene-based multi-trait associations. All suggestive associations 















Both gene-based and single variant tests were generally well calibrated, however 
no transcripts and only four single variants attained exome-wide significance criteria 
across the 28 traits and multi-trait analyses. One of these rs117042905 in ARHGAP39 is 
associated with WHR in males adjusted for BMI at the second visit. Due to the limited 
number of men without diabetes at visit 2, the samples size was only 89, making this test 
underpowered and subject to error.  
Phenotypes at the two visits are correlated, and we would expect to see similar 
effect sizes across the visits for true associations. With the exception of OLR1, the top 
signals the betas are directionally consistent at the other time point, with the exception of 
PC2 and PC3 where directionality is flipped, as explained in chapter 2. Fourteen of the 
twenty-one suggestive single variant associations are also nominally (p < 0.05) 
associated with the same trait at the other visit. For gene-based associations, nine of 
eleven gene-based signals with a second time point are also nominally associated at the 
other time point. While this is not independent replication, lack of consistent association 
at the other time point casts doubt for common variants. For rare variants this is less 
concerning; the carriers missing from the second time point have a larger impact on the 
association test than for common variants.  
GABRA6 p.Arg92His, which is associated with WHR at visit 2, is physically 
close to GABRB2, which contains single variants also associated with WHR at visit 2 
(Chapter 3). Both GABRA6 and GABRB2 are subunits of the GABAA receptor. The 
relationship between these variants will be further investigated (Chapter 5).  
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Additional associations are also part of neuronal signaling or neuronal 
development. The gene GCM2 was suggestively associated with PC3 at visit 1 in the 
gene-based association test of protein truncating variants and rare non-synonymous 
variant. GCM2 serves as a switch in neuronal development, which determines if cells 
become neurons or glial cells, the insulating cells along neural axons that make long-
range signal transduction possible(201). Deletion of this gene in humans has been 
reported to cause familial isolated hypoparathyroidism, which is characterized by 
hypocalcemia(202). This gene is involved in development; genes involved in neuronal 
signaling throughout life were also associated with obesity related traits. A common 
variant in TRAK1, rs4234445, was suggestively associated with PC2 at visit 1. This 
replicates a prior association with subcutaneous adipose tissue to visceral adipose tissue 
ratio. The gene is known to be involved in trafficking of receptors, particularly GABAA 
receptors, to and from the cell membrane(203, 204). One gene from the multi-trait gene-
based analysis, DLG4, is known to play a role in maintenance of the synaptic junction; 
interestingly this gene is overlapping in a head to head orientation with ACADVL, which 
is involved in β-oxidation of long-chain fatty acids(205). Coding variants in ACADVL 
were not associated with any adiposity traits, however based on these observations 
multiple mechanisms for variants in this locus impacting adiposity are possible. 
Rare coding variants in another gene involved in fatty acid metabolism, ACSL1, 
were suggestively associated with PC3 at visit 1 and nearly attained suggestive 
association at the second visit as well. The gene product, long chain acyl-CoA synthetase 
1, is important for both β-oxidation of long-chain fatty acids and the synthesis of cellular 
lipids(206). Based on the gene’s function it was hypothesized to cause lipodystrophy, 
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however adipose tissue specific knock out mice have the same mass as their littermates, 
but higher percentage body fat(207). The knock out mice were unable to maintain their 
body temperature in a cold environment and had lower fatty acid oxidation rates(207). 
This indicates that disruption of fatty acid oxidation and triglycerides can change amount 
of body fat, as well as disrupt the normal physiological function of adipose tissue. 
Both the multi-trait analysis and the composite measures of adiposity provided 
biologically compelling associations signals; however, the composite measures provided 
more associations including replication of an association with subcutaneous adipose 
tissue to visceral adipose tissue ratio. This is a measure that is typically expensive and 
time consuming to measure. This suggests that some approximation of this can be 
obtained from PC2, which utilizes routine non-invasive measures of adiposity. 
While other significant and suggestive associations form the exome sequencing 
analyses lack readily apparent biological links to obesity, the top signals should be 
followed up in a replication sample set before further investigating the biological impact 
of the variants. The replication sample set should be carefully matched to the same 
ancestry group because many rare variants are unique to a single ancestry group. A set of 
2000 individuals from Starr County is currently undergoing whole-exome sequencing 
and would make an ideal replication data set. The current analyses are restricted to 
individuals without a diagnosis of diabetes. Using individual with type 2 diabetes for 
replication is far from ideal, due to the impact of diabetes medications and behavioral 
interventions on obesity related traits, but would be easily accessible.  
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Chapter 5: Conditional Analysis of Overlapping Loci 
INTRODUCTION 
Once an association signal is identified, the next step is to develop hypotheses of 
what molecular changes are induced and identify an effector transcript. In the past, 
candidate variants have been obtained through sequencing genes in close proximity to 
strong signals. Since most individuals in this genome-wide chip data set also have whole 
exome sequencing data, we can look at these two types of data together without having 
to limit to the very strongest signals. Given that we have already tested for single variant 
associations exome wide, a first pass screen of looking for physical overlap of top 
signals from the imputed data and exome sequencing data is a good starting point. While 
this can be quickly ascertained by visual inspection of Manhattan plots, additional 
investigation to assess the size of regions and the linkage disequilibrium (LD) pattern 
between variants is required. Signals from the imputed data that are not seen in the 
exomes may either be spurious signals, or are not well captured by the targeted exome 
sequencing. Either way investigating the sequencing data is not informative.  
Traditionally, a causative variant should be one of if not the strongest 
association. In this case, it is possible for other variants to have stronger associations due 
to the smaller sample size of the exome sequencing data. It is also possible for a single 
gene to contain multiple causative variants, which depending on the LD pattern between 






Overlap of signals across the genome wide chip data and exome sequencing data 
was assessed by visual comparison of Manhattan plots for the same trait and visit. To 
understand these loci, analyses in the region were repeated, conditioning on the lead 
variants in both the sequencing and chip data, as well as biologically interesting variants 
such as nonsynonymous variants when they are available. Regions were visualized both 
before and after conditioning on candidate variants using the stand-alone version of 
LocusZoom v1.3 (http://genome.sph.umich.edu/wiki/LocusZoom_Standalone), which 
creates Manhattan plots of small regions including information on LD, genes in the 
region, and previously published GWAS hits(208).  
RESULTS 
There was no over-lapping top signals between the common variant gene based 
test (VEGAS) applied to the genome wide data and the rare variant gene-based test 
(SKAT-O) results from the exomes sequencing data. The lack of common associations is 
reflective of the different hypotheses tested by the different methods. In VEGAS we 
expect to detect multiple independent common signals in the same gene, where as in 
SKAT-O look for association grouping rare, putatively functional variants. 
Nine regions were identified as having single variant signals in both the whole 
exome sequencing data and the genome-wide chip data imputed to 1000 Genomes. This 
includes a region on chromosome 22 including CYB5R3 and POLDIP3 that is associated 
with BMI, percent body fat, and arm circumference all at the first visit; WIPF3 
associated with BMI and waist circumference at visit 1; and GABRB2 and GABRA6 
associated with WHR with and without adjusting for BMI. Results are shown in the form 
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of LocusZoom regional plots. Variants from the exome sequencing data are shown as 
solid circles while results form the genome-wide chip data imputed to 1000 Genomes are 
shown as open circles. The coloring of the points represents LD with the lead variant. 
For example, looking at Figure 32A, the plot spans the length of the entire gene 
COL24A1. The lead SNP, rs1911545, is represented by a purple circle; other variants are 
colored based on their LD with this SNP, with red being the highest r2 and dark blue 
being the lowest. The blue vertical lines represent recombination rates. 
A region on chromosome 1, which contains COL24A1 is near-suggestively 
associated with PC3 at visit 1 in both exome sequencing and chip data. A closer look 
revealed two protein altering variants, rs11161732 (COL24A1 p.Pro546Ser) and 
rs56046090 (COL24A1 p.Thr328Lys). The lead most significant variant, rs1911545 is in 
linkage disequilibrium with rs11161732 (r2 = 0.49). Conditioning on rs11161732 (Figure 
32 B) attenuated some of the signal, but signal remained. By conditioning on 
rs56934354 (Figure 32 C) it appears the complimentary signal was attenuated; this was 
confirmed by conditioning on both variants simultaneously (Figure 32 D). This indicates 
there may be two independent signals in this gene, which both include nonsynonymous 
variants.  
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A.	 	 	 	 	 	 B.	
		C.	 	 	 	 	 	 D.	
	
Figure 31. COL24A1 association with PC3 at visit 1. The panels show associations of 
PC3 at visit 1 in the region of COL24A1 A) without conditioning on any variants, B) 
conditioning on rs11161732, C) conditioning rs56046090, and D) conditioning on both 
rs11161732 and rs56046090. Open circles represent genome wide chip variants; solid 
circle represent exome sequencing variants. The point color reflects linkage 
disequilibrium with the top variant. All points are grey in panel B due to lack of LD 
information in 1000 Genomes on the top variant. 
Variants on chromosome 21 near DSCAM are associated with PC3, which 
captures central verses peripheral adiposity at visit 2. Upon conditioning on the rare 
intronic variant, rs78085341 in DSCAM, (Figure 33); no association signal persists. This 























































86.2 86.3 86.4 86.5 86.6

















































86.2 86.3 86.4 86.5 86.6



























● ● ● ● ●● ● ●
●


















86.2 86.3 86.4 86.5 86.6





















































86.2 86.3 86.4 86.5 86.6
Position on chr1 (Mb)
 132	
across both sequencing and chip data. The prior association with “Obesity related traits” 
shown on the plot is with arm span and height in Hispanic children. DSCAM is primarily 
expressed in the pituitary gland and brain tissues(209).  
A.	 	 	 	 	 	 B.	
	
Figure 32. DSCAM association with PC3 at visit 2. The panels show associations of 
PC3 at visit 2 in the region of DSCAM A) without conditioning on any variants, and B) 
conditioning on rs78085341. Open circles represent genome wide chip variants; solid 
circle represent exome sequencing variants. The point color reflects linkage 
disequilibrium with the top variant. 
A region including WIPF3 on chromosome 7 is associated with both BMI and 
waist circumference at visit 1. These are highly correlated traits (r2=0.87). For 
simplicity, results are shown for waist circumference, which had a slightly stronger 
association (Figure 34). By conditioning on the lead variant, rs2301922, there is no 
remaining signal, indicating one driving haplotype. The “Obesity-related traits” 
indicated as previously associated in the plot is actually a sleep respiratory quotient in 
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A.	 	 	 	 	 	 B.	
	
Figure 33. WIPF3 associtation with waist circumference at visit 1. Association with 
waist circumference at visit 1 and variants in the region of WIPF3 are shown A) without 
conditioning on any variants and B) conditioning on rs2301922. Open circles represent 
genome wide chip variants; solid circle represent exome sequencing variants. The point 
color reflects linkage disequilibrium with the top variant. 
A region on chromosome 3 containing GK5 is suggestively associated with WHR 
in females at visit 1 both with and without adjusting for BMI (see Table 13). 
Conditioning on the lead variant, rs9857725, attenuated all signal in the region (Figure 
35). This lead variant is intronic and no coding variants are included in the haplotype 
block. Intronic variants can alter expression in many ways including altering 
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A.	 	 	 	 	 	 B.	
	
Figure 34. GK5 association with WHR at visit 1 in females. Associations with WHR 
in females at visit 1 with variants near GK5 are shown A) without conditioning on any 
variants and B) conditioning on rs9857725. Open circles represent genome wide chip 
variants; solid circle represent exome sequencing variants. The point color reflects 
linkage disequilibrium with the top variant. All points are grey in panel B due to lack of 
LD information in 1000 Genomes on the top variant. 
Variants on chromosome 12 in and near OLR1 are associated with WHR in 
females at visit 1. After conditioning on rs3736235, the lead variant from analysis of the 
exome sequencing data, the signal in attenuated (Figure 36). The common variant gene-
based test for OLR1 was also suggestively associated with WHR in females at visit1. 
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A.	 	 	 	 	 	 B.	
	
Figure 35. OLR1 association with WHR in females at visit 1. Associations with WHR 
in females at visit 1 with variants near OLR1 are shown A) without conditioning on any 
variants and B) conditioning on rs3736235. Open circles represent genome wide chip 
variants; solid circle represent exome sequencing variants. The point color reflects 
linkage disequilibrium with the top variant. 
Despite the low number of males, two regions were associated with WHR 
adjusting for BMI in males in both the sequencing and chip data. At visit 1, ECE1 on 
chromosome 1 is associated in both genetic data types. Conditional analyses indicate 
there are two regions of the gene independently associated with WHR adjusted for BMI 
in males. The first is represented by the lead SNP in the exome sequencing data, 
rs1076669; this is a nonsynonymous variant causing amino acid residue 341 to change 
from threonine to isoleucine. Conditioning on ECE1 p.Thr341Ile attenuates all the signal 
in the 3’ part of the gene, but a stronger signal about 100 kilobases away in the promoter 
region of the gene remains (Figure 37 B). After conditioning on the common intergenic 
variant, rs12137689 in the genome-wide chip data, the promoter signal is diminished 
(Figure 37 C). This indicates there are two separate signals, one coming form the 
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promoter region of ECE1. The second male specific WHR association signal comes 
from visit 2, where we observe an association with variants in an near TRIOBP (Figure 
38); this association is attenuated after conditioning the on rs739138, the top variant 
from the whole exome sequencing analyses. This variant is a nonsynonymous variant, 
changing residue 1300 from histidine to arginine. 
A.	 	 	 	 	 	 B.	
		C.	
	
Figure 36. ECE1 association with WHR adjusted for BMI in males at visit 1. 
Associations with WHR in males at visit 1 with variants near ECE1 are shown A) 
without conditioning on any variants, B) conditioning on rs1076669 (ECE1 
p.Thr341Ile), and C) conditioning on rs12137689 in the imputed data. Open circles 
represent genome wide chip variants; solid circle represent exome sequencing variants. 
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A.	 	 	 	 	 	 B.	
	
Figure 37. TRIOBP association with WHR adjusted for BMI in males at visit 2. 
Associations with WHR in males at visit 2 with variants near TRIOBP are shown A) 
without conditioning on any variants and B) conditioning on rs739138. Open circles 
represent genome wide chip variants; solid circle represent exome sequencing variants. 
The point color reflects linkage disequilibrium with the top variant. 
On chromosome 22, a region containing both CYB5R3 and POLDIP is associated 
with arm circumference, BMI, and percent body fat at visit 1. Results shown in Figure 
39 are for arm circumference, where the association is strongest, but the pattern is the 
same in all three traits. After conditioning on rs5996200, the top signal coming from the 
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A.	 	 	 	 	 	 B.	
	
Figure 38. CYB5R3 associations with arm circumference at visit 1. Associations with 
arm circumference at visit 1 with variants near CYB5R3 are shown A) without 
conditioning on any variants and B) conditioning on rs5996200. Open circles represent 
genome wide chip variants; solid circle represent exome sequencing variants. The point 
color reflects linkage disequilibrium with the top variant. 
Lastly, a region on chromosome 5 containing both GABRB2 and GABRA6 is 
associated with WHR at visit 2. The variant with the strongest association is 
rs150769823, a low-frequency intronic variant with a borderline imputation quality (info 
= 0.72). In the exome sequencing data, the lead variant is the low frequency 
nonsynonymous variant, rs3811993, which changes threonine at residue 187 of GABRA6 
to methionine (Figure 40). This variant was also imputed in the chip data, however the 
imputation quality excluded it from further consideration (info = 0.59) and due to poor 
concordance could not be used for conditional analyses. The lead variant from the 
imputed data, rs150769823 was not captured by the exome sequencing data. 
Conditioning on either of the lead variants attenuates other signal in the region for the 
respective datasets. The high LD between the two variants (r2 = 0.88), suggests they may 
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Figure 39. GABRB2 and GABRA1 association with WHR at visit 2. Associations 
with WHR visit 2 with variants near GABRB2 and GABRA1 are shown A) without 
conditioning on any variants and B) conditioning on rs3811993 in the sequencing data 
and C) conditioning on rs150769823 in the imputed data. Open circles represent genome 
wide chip variants; solid circle represent exome sequencing variants. The point color 
reflects linkage disequilibrium with the top variant. 
DISCUSSION 
Through conditional analysis of nine loci clearly associated with the same traits 
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account for the association signal ion the region were identified for four of the sites 
(Table 20).  
Traits Locus summary 
PC3 v1 COL24A1 Two idependent signals p.Thr328Lys 
and p.Pro546Ser 
PC3 v2 DSCAM One intronic signal 
BMI v1 wasit V1 WIPF3 One intronic signal 
WHR females v1 GK5 One intronic signal 
WHR females v1 OLR1 One intronic signal 
WHR adj BMI males 
v1 
ECE1 Two independent singals, p.Thr341Ile 
and promoter region 
WHR adj BMI males 
v2 
TRIOBP One signal p.His1300Arg 
arm circumference v1 CYB5R3 One signal, synonymous variant 
rs5996200 
WHR v2 GABRB2/GABRA6 High LD between GABRA6 
p.The187Met, and intronic GABRB2 
varaiants 
Table 20. Conditional analysis conclusions. 
Two nonsynonymous variants in COL24A1 are independently associated with 
PC3 at visit 1. Neither of these variants quite reach exome-wide suggestive criteria, 
however due to the consistent effect seen in both the genome-wide chip data and exome 
sequencing data they are still of interest. The gene encodes a collagen that, in the mouse, 
is most expressed in the bone, retina, tendon, skin, and cornea (210). As discussed in 
chapter 2, PC3 at visit 1 measures central versus peripheral adiposity. The positive effect 
size for rs11161732 (β (SE) = 0.10 (0.03), MAF= 0.37) indicates that carriers have a 
higher in peripheral circumferences and lower central circumferences. In contrast the 
rare variant rs56046090 (β (SE) = -0.50 (0.13), MAF= 0.009) reflects the opposite. This 
may reflect differences in fat-free mass composition, such as bone density, that would 
require additional measures to further investigate. 
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Conditional analyses of regions associated WHR adjusted for BMI in males, one 
locus for each visit, each led to identification of putative functional nonsynonymous 
variants. The association with TRIOBP and WHR adjusted BMI for males at visit 2 may 
be defined by a single variant, rs739138 p.His1300Arg. This gene encodes many 
isoforms. While protein truncating variants in this gene are known to cause autosomal 
recessive nonsyndromic hearing loss (211, 212), the exon containing this variant is not 
part either isoform expressed in the ear, TRIOBP4 and TRIOBP5 (213). TRIOBP is 
involved in the regulation of cell migration, cell growth, and cytoskeletal 
organization(214). The association with WHR adjusted for BMI at visit 1 with ECE1 has 
two independent regions, one in the promoter, the other may be defined by rs1076669, 
p.Thr341Ile. Mutations in this gene have been tied to Hirschprung disease and essential 
hypertension(215, 216). ECE1 knock out mice have a variety of malformations including 
a lack of enteric neurons in the distal gut, consistent with Hirschprung disease(217). The 
mutation previously identified as causing Hirschprung disease is Arg754Cys, which lies 
on the opposite side of the protein as the variant reported here. It would be plausible that 
this variant has lesser effect on enteric neurons. 
The final locus with a protein altering variant potentially accounting for the 
association with WHR at visit 2 is the GABRA6 locus. As discussed in chapter 3 the 
GABAA receptor is a heteropentamer	that	acts	as	a	major inhibitory synaptic signal 
transmission in the nervous system(183).	The	specific	α and γ isoforms present 
determine the molecule’s ability to bind modulators such as benzodiazepine	and	
ethanol.	The	α6 isoform is classified as diazepam-insensitive(184). Mutations in some 
isoforms have been reported to cause epilepsy (GABRA1, GABRG2, GABRD), increased 
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risk of alcohol dependence (GABRA2)(218-224). GABRA6 has not previously been 
reported as associated with in any phenotypes. As discussed in chapter 3 disruption of 
signaling through GABAA receptor alters inhibitory signals to the hypothalamo–
pituitary–adrenocortical axis, which may result in obesity. Further, recent work on 
mouse models shows that the neurons of lateral hypothalamus that produce GABA play 
a key role in compulsive sucrose seeking behaviors.(225, 226) 	
The other loci where conditional analyses were run did not have a 
nonsynonymous variant as clear candidate functional variant. However there are other 
means by which a variant can impact a trait. For example the intronic variants in WIPF3 
fall into an enhancer region. A variant that alters enhancer binding may subsequently 
impact expression levels. Investigation of the transcript levels of these genes in the 
GTEx portal shows that the lead variants in COL24A1 (rs11161732 p = 7.6 × 10-9, tibial 
artery), and TRIOBP (rs739138 p = 5.8 × 10-7, whole blood), and CYB5R3 (rs5996200 p 
= 1.7 × 10-6, esophagus mucosa) are all three cis-acting eQTLs, meaning they are 
associated with mRNA levels of the gene the variant lies in(209). Other possible 
mechanisms include altered promoter, repressor, or transcription factor binding. There 
are also encoded regulatory elements within introns, such as miRNA that are 
incompletely understood. 
While conditional analyses clarify the relationship between variants in a region 
they do not indicate if the signal is real. Many of these are suggestive associations, and 
to establish these as obesity related variants independent replication is required. For very 
rare variants, ascertainment of family members will enrich the sample for carriers 
increasing power to detect an association. In the case that protein-altering variants have 
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been elucidated as likely candidates, follow up work functional work is required to 
establish causation. The use of existing biological information on the genes is useful for 
establishing the role of the gene in adiposity.  
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Chapter 6: Monogenic Obesity 
INTRODUCTION 
As reviewed in Chapter 1 and Table 2, there are three broad classes of 
monogenic adiposity: isolated obesity, lipodystrophy, and syndromic obesity. There are 
81 genes identified as causing a monogenic disorder which features obesity or 
lipodystrophy. Many of these are autosomal recessive disorders that, in the heterozygous 
state, may have an impact on body fat amount and distribution, albeit much smaller. 
There is evidence that less detrimental variants in these genes, particularly MC4R, may 
have smaller effects on body fat distribution (43). With the prior information that these 
genes are likely to impact obesity and fat distribution, a more careful look at these genes 
is warranted irrespective of any other associations of lack thereof seen in the prior 
analyses of genome wide markers and exome sequencing. In this chapter, however, we 
will focus on the arrays of mutations found in these 81 genes at look at them individually 
and in aggregate. We will examine their impact on the full set of phenotypes as there 
may be effects in either the amount or distribution of body fat of both.  
The exome sequencing data provides information about the coding variation, 
however intronic variation may alter gene expression thus having an impact on adiposity 
as well. Therefore we will look at the single variant associations from the imputed data 
as well as taking a deeper look at the whole exome sequencing data. 
METHODS 
Gene set definition: The monogenic adiposity genes listed in Table 2 were 
obtained through literature search and Online Mendelian Inheritance in Man 
(www.omim.org). Genes were classified as implicated in causing isolated obesity, 
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lipodystrophy or syndromic obesity based on published descriptions as referenced in 
Table 2; a single gene could fall in multiple categories (Table 21). 
Array of variation: The number of variants and counts by annotation were pulled 
from the whole exome sequencing data using PLINK\SEQ 
(https://atgu.mgh.harvard.edu/plinkseq/) for all 1,490 Starr County individuals with 
exome sequencing data, regardless of diabetes status. The transcript with the most 
deleterious annotation was used for each variant. For example, rs117372135 is a 
missense variant in two of five MCHR1 transcripts. For the other transcripts this variant 
is noncoding due to alternative splicing. We considered the most deleterious variant 
when looking at the amount of variation since this is the form in which the variant is 
most likely to have a large impact on the functionality of the gene-product. 
Enrichment: To test for enrichment of association signal in monogenic adiposity 
genes, genomic inflation factors () were calculated for variants in each of the three 
subsets of genes (isolated obesity, lipodystrophy, and syndromic obesity) and the full list 
of genes as shown in Table 21 for each obesity related traits. This was performed 
separately on the genome wide chip data imputed to 1000 Genomes and whole exome 
sequencing results. As with previous analyses, genes on chromosome X were not 
included. To assess the significance of inflation or deflation single variant analyses and 
genomic inflation factors were calculated for 1,000 simulated N~(0,1) outcomes for the 
same subsets individuals. This allows us to assess the frequency with which enrichment 
or depletion as extreme as we observed would be observed by chance alone in these 
particular sets of genes and individuals.  
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Global test of association: To evaluate the role of rare coding variants in the 
autosomal genes, SKAT-O analyses were conducted combining the variants across each 
gene set into a single gene based test. This was done for all three masks (Table 13 in 
Chapter 4) and each of the four gene sets.  
gene position stop gain missense splice synonymous all gene sets 
LMNA chr1:156052336-156109880 0 (0) 5 (4) 1 (1) 9 (4) 32 (16) lpd 
SDCCAG8 chr1:243419306-243663393 0 (0) 12 (9) 2 (2) 9 (5) 36 (24) synd 
CCDC28B chr1:32665986-32670991 0 (0) 13 (9) 2 (1) 7 (5) 28 (21) synd 
ZMPSTE24 chr1:40723721-40759856 1 (1) 3 (3) 1 (1) 2 (1) 18 (14) lpd 
LEPR chr1:65886334-66103176 0 (0) 19 (14) 1 (1) 13 (10) 56 (38) ob 
H6PD chr1:9294862-9331394 0 (0) 29 (23) 2 (2) 30 (19) 66 (48) synd 
BBS5 chr2:170336005-170363165 0 (0) 9 (6) 2 (1) 5 (3) 28 (20) synd 
GPR35 chr2:241544824-241570676 2 (1) 25 (15) 0 (0) 11 (4) 47 (26) synd 
POMC chr2:25383721-25391559 0 (0) 7 (5) 0 (0) 4 (2) 12 (8) ob 
WDPCP chr2:63348534-63815867 0 (0) 14 (9) 5 (4) 0 (0) 35 (25) synd 
ALMS1 chr2:73612885-73837046 2 (1) 87 (57) 1 (1) 46 (31) 162 (104) synd 
PPARG chr3:12329348-12475855 0 (0) 5 (2) 2 (2) 11 (10) 29 (21) lpd 
SLC2A2 chr3:170714136-170744768 0 (0) 8 (5) 1 (1) 6 (3) 24 (13) synd 
THRB chr3:24158644-24536313 0 (0) 4 (2) 1 (1) 4 (2) 19 (10) synd 
LZTFL1 chr3:45864809-45957216 0 (0) 11 (8) 0 (0) 5 (4) 26 (19) synd 
ARL6 chr3:97483364-97520086 0 (0) 1 (1) 1 (1) 0 (0) 9 (6) synd 
CIDEC chr3:9908393-9921938 1 (1) 2 (2) 0 (0) 4 (2) 11 (7) lpd 
BBS7 chr4:122745483-122791652 1 (1) 12 (11) 1 (0) 3 (2) 28 (20) synd 
BBS12 chr4:123653856-123666098 0 (0) 22 (13) 1 (1) 10 (2) 35 (17) synd 
FGFR3 chr4:1795038-1810599 0 (0) 11 (9) 7 (3) 24 (15) 87 (59) synd 
PROP1 chr5:177419235-177423243 0 (0) 6 (4) 1 (0) 4 (2) 14 (9) synd 
PCSK1 chr5:95726039-95768985 0 (0) 9 (4) 1 (1) 8 (6) 34 (26) ob 
SIM1 chr6:100836749-100911551 0 (0) 17 (10) 0 (0) 9 (7) 36 (23) ob;synd 
PSMB8 chr6:32808493-32812712 0 (0) 14 (12) 3 (1) 8 (6) 33 (25) lpd 
RAB23 chr6:57051790-57087112 1 (1) 4 (2) 1 (1) 1 (1) 17 (15) synd 
MRAP2 chr6:84743419-84800605 0 (0) 6 (6) 2 (1) 2 (0) 12 (8) ob 
CAV1 chr7:116164838-116201239 0 (0) 2 (0) 0 (0) 4 (3) 12 (7) lpd 
LEP chr7:127881330-127897682 0 (0) 3 (2) 0 (0) 6 (5) 14 (9) ob 
CRHR2 chr7:30691558-30739719 0 (0) 8 (4) 0 (0) 3 (2) 19 (11) ob 
GHRHR chr7:31003635-31019146 0 (0) 5 (1) 2 (2) 9 (7) 33 (17) synd 
BBS9 chr7:33169151-33645680 0 (0) 24 (16) 4 (3) 15 (13) 62 (44) synd 
VPS13B chr8:100025493-100889814 1 (0) 64 (49) 6 (5) 42 (24) 168 (120) synd 
TMEM67 chr8:94767071-94831460 2 (2) 10 (7) 3 (2) 6 (4) 45 (32) synd 
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gene position stop gain missense splice synonymous all gene sets 
TRIM32 chr9:119449580-119463579 0 (0) 15 (15) 0 (0) 5 (4) 21 (20) synd 
AGPAT2 chr9:139567594-139581911 0 (0) 7 (5) 1 (1) 9 (8) 36 (27) lpd 
NTRK2 chr9:87283372-87641985 0 (0) 8 (7) 4 (3) 9 (6) 42 (32) ob 
BBIP1 chr10:112658487-112679124 0 (0) 0 (0) 0 (0) 0 (0) 2 (2) synd 
BDNF chr11:27676441-27743605 0 (0) 5 (3) 0 (0) 1 (0) 10 (6) ob;synd 
PAX6 chr11:31806340-31839509 0 (0) 4 (3) 2 (2) 9 (6) 26 (18) synd 
WT1 chr11:32409321-32457081 0 (0) 3 (3) 0 (0) 5 (2) 18 (10) synd 
BSCL2 chr11:62457733-62477091 0 (0) 9 (5) 2 (2) 11 (10) 35 (23) lpd 
MEN1 chr11:64570985-64578766 0 (0) 13 (9) 1 (1) 8 (4) 30 (17) synd 
BBS1 chr11:66278118-66301084 0 (0) 13 (9) 3 (2) 8 (5) 43 (33) synd 
TBX3 chr12:115108058-115121969 0 (0) 5 (5) 0 (0) 12 (5) 22 (13) synd 
BBS10 chr12:76738265-76742222 0 (0) 9 (7) 0 (0) 1 (1) 11 (9) synd 
CEP290 chr12:88442789-88535993 1 (1) 29 (21) 8 (7) 9 (4) 69 (45) synd 
TTC8 chr14:89290496-89344340 0 (0) 7 (6) 2 (1) 5 (5) 24 (19) synd 
MKRN3 chr15:23810453-23813166 0 (0) 10 (9) 0 (0) 7 (6) 17 (15) synd 
MAGEL2 chr15:23888695-23892993 0 (0) 12 (11) 0 (0) 5 (4) 18 (16) synd 
NDN chr15:23930553-23932450 0 (0) 4 (4) 0 (0) 5 (4) 11 (10) synd 
SNRPN chr15:25068793-25223729 0 (0) 1 (1) 1 (1) 5 (4) 26 (16) synd 
SNORD116-1 chr15:25296622-25296719 0 (0) 0 (0) 0 (0) 0 (0) 6 (4) synd 
IPW chr15:25361691-25367623 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) synd 
UBE3A chr15:25582395-25684175 0 (0) 5 (5) 0 (0) 5 (2) 19 (14) synd 
GABRG3 chr15:27216428-27778373 0 (0) 4 (2) 2 (2) 11 (3) 25 (10) synd 
BBS4 chr15:72978519-73030817 0 (0) 13 (11) 3 (2) 7 (6) 35 (22) synd 
PLIN1 chr15:90207599-90222648 0 (0) 12 (7) 1 (1) 4 (1) 26 (17) lpd 
BBS2 chr16:56518258-56554008 0 (0) 4 (1) 1 (0) 8 (7) 30 (16) synd 
PMM2 chr16:8891669-8943194 1 (0) 13 (11) 1 (1) 4 (2) 35 (28) lpd 
PTRF chr17:40554466-40575338 1 (1) 4 (4) 0 (0) 5 (4) 10 (9) lpd 
CRHR1 chr17:43861645-43913194 0 (0) 9 (7) 0 (0) 4 (1) 33 (19) ob 
MKS1 chr17:56282796-56296966 0 (0) 15 (12) 0 (0) 2 (1) 31 (22) synd 
GH1 chr17:61994552-61996212 0 (0) 5 (4) 1 (1) 9 (8) 33 (23) synd 
PRKAR1A chr17:66409763-66547457 0 (0) 18 (15) 3 (3) 15 (12) 76 (57) synd 
MC4R chr18:58038563-58040001 0 (0) 14 (9) 0 (0) 2 (2) 17 (12) ob 
AKT2 chr19:40736223-40791302 0 (0) 9 (9) 4 (4) 7 (6) 56 (41) lpd 
MEGF8 chr19:42829760-42882921 0 (0) 42 (33) 10 (7) 40 (25) 109 (78) synd 
INSR chr19:7112265-7294011 0 (0) 12 (11) 6 (3) 36 (15) 81 (41) synd 
MKKS chr20:10385427-10414887 0 (0) 13 (11) 0 (0) 6 (3) 27 (19) synd 
MC3R chr20:54823787-54824871 1 (1) 7 (5) 0 (0) 5 (5) 18 (13) ob 
GNAS chr20:57414794-57486250 1 (1) 19 (17) 2 (2) 26 (19) 60 (47) synd 
IFT27 chr22:37154245-37172177 0 (0) 4 (4) 0 (0) 2 (1) 12 (7) synd 
MCHR1 chr22:41075181-41078818 1 (1) 13 (9) 0 (0) 8 (6) 26 (18) ob 
GPC4 chrX:132435063-132549205 0 (0) 5 (3) 1 (1) 1 (1) 11 (5) synd 
GPC3 chrX:132669775-133119673 0 (0) 7 (5) 2 (1) 6 (4) 19 (14) synd 
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gene position stop gain missense splice synonymous all gene sets 
PHF6 chrX:133507341-133562822 0 (0) 2 (2) 2 (1) 3 (3) 13 (9) synd 
OFD1 chrX:13752831-13787480 0 (0) 11 (11) 0 (0) 6 (4) 34 (27) synd 
FMR1 chrX:146993468-147032647 0 (0) 5 (4) 1 (0) 3 (2) 21 (12) synd 
MECP2 chrX:153287263-153363188 0 (0) 15 (13) 1 (1) 13 (9) 30 (23) synd 
HDAC8 chrX:71549365-71792953 0 (0) 2 (2) 0 (0) 5 (2) 15 (10) synd 
CHM chrX:85116184-85302566 0 (0) 8 (5) 2 (1) 6 (4) 25 (16) synd 
Table 21. Monogenic adiposity genes. In parentheses are the numbers of variants with 
a MAC<6. Abbreviations: MAC: minor allele count, synd: syndromic obesity genes, lpd: 
lipodystrophy genes, ob: isolated obesity genes. 
RESULTS 
 Across all monogenic obesity genes, very few protein-truncating variants were 
observed (Table 21). Phenotypic traits of carriers were assessed directly by inspection to 
see if carriers were obvious outliers with regard to their phenotypes. Only one man 
carrying a protein-truncating variant in one of these genes, MCHR1, stood out as having 
and extremely high BMI of 53.1 kg/m2 at the age of 18. His BMI remained high 
throughout adulthood, with a dip down to 38.1 at age 79. Despite having an 
extraordinarily high BMI he was not diagnosed with diabetes until he was in his mid 
70s. Mutations in MCHR1 are reported not only to increase risk for severe early onset 
obesity, but also some loss of function mutations have been identified in underweight 
individuals(227, 228). 
To assess the overall impact of these variants, the results from previous single 
variant analyses in both the imputed and exomes data sets were looked at for each gene 
set, allowing us to look outside the confidence bands instead of applying a strict 
significance threshold. Few variants clearly lay outside of the confidence bands on gene-
set specific QQ-plots. From the genome-wide chip data imputed to 1000 Genomes, this 
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include variants in the syndromic obesity genes VPS13B and WDPCP for PC2 at visit 1 
(Figure 41 A), TRIM31, SDCCAG8, CEP290, and SNRPN with percent body fat at visit 
1 (Figure 41 B), INSR and SNRPN with percent body fat at visit 2 (Figure 41 C), and the 
isolated obesity genes LEP and NTRK2 with PC3 at visit 2 (Figure 41 D).  
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A.      B. 
 
C.      D. 
 
Figure 40. Monogenic variants outside of confidence bands from genome-wide 
imputed data single variant tests.  
Similar analyses in the exome sequencing data, show variants laying above the 
confidence bands were in the isolated obesity MC3R and MCHR1 for PC2 at visit 1 
(Figure 41 A) and the syndromic obesity genes BBS2 and VPS13B for PC2 at visit 1 
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(Figure 41 B). At least one of the top variants in each of these genes from the exome 
sequencing data is a nonsynonymous variant. 
A.	 	 	 	 	 	 B.	
 
Figure 41. Monogenic variants outside of confidence bands from exome sequencing 
single variant tests.  
 In both the exome sequencing and genome-wide chip data the lipodystrophy gene 
LMNA falls above the confidence bands in the sex specific analyses, interestingly the 
betas for these variants are positive in females and negative in males (Figure 42). This 
reflects the sexually dimorphic nature of WHR where men tend to typically increase 
WHR with increasing weight and women gain weight on their hips, thus decreasing 
WHR. LMNA is a lipodystrophy gene affecting fat deposit location and size, making 




A.     C. 
  
C.     D.  
 
Figure 42. lipodystrophy gene variants sex-specific association with WHR.  
In addition to looking for variants that fall outside the confidence bands on the 
QQ plots, the gene-set specific  provides insight into systematic inflation or deflation. 
Across the combination of gene sets and traits, both enrichment and depletion were 
observed with  ranging from 0.58 to 1.70 (Table 22), however this does not tell us if the 
enrichment or depletion is significant. Some of sets are small, with the lipodystrophy 
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gene set containing as few as 29 variants with a minor allele count of 5 or more. Further, 
the sample size drops to 89 for male-specific analyses at visit 2. To assess significance, 
analyses were repeated on 1,000 simulated N~(0,1) traits for the same individuals. Only 
seven gene set and trait combinations were nominally significant (p-value <0.05); none 
remained significant after correcting for multiple testing.  
The nominally significant tests are in bold text in Table 22. In the genome-wide 
imputed data, waist circumference at visit 1 p-values in isolated obesity genes were 
deflated with a  = 0.73. Similarly, WHR at visit 1 p-values for isolate obesity genes 
were deflated with a  = 0.77 (p = 0.036). For PC2 at visit 1, p-values in all monogenic 
obesity genes are inflated, with a  = 1.12 (p = 0.044). The smallest p-values in this gene 
set reside in VPS13B, which causes Cohen Syndrome, or WDPCP, which is thought to 
modify Bardet-Biedl syndrome(58, 67).  
In the exome sequencing data, WHR in females at visit 2 p-values in both the 
isolated obesity and all monogenic obesity gene sets are deflated, with  = 0.58 (p = 
0.014) and  = 0.84 (p = 0.034), respectively. PC3 at visit 2 p-values in isolated obesity 
genes are deflated with  = 0.61 (p = 0.022). PC2 at visit 2 p-values were inflated with  
= 1.65 (p = 0.020); the variants with the smallest p-values are in LMNA. 
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genome-wide imputed data sequencing 
all isolated lipodystrophy syndromic all isolated lipodystrophy syndromic 
Trait  P-value  P-value  P-value  P-value  P-value  P-value  P-value  P-value 
arm visit 1 0.99 1.000 0.83 0.142 0.80 0.186 1.06 0.464 1.02 0.696 0.83 0.380 1.15 0.352 1.03 0.636 
arm visit 2 1.00 1.000 0.82 0.144 1.15 0.338 1.03 0.650 1.01 0.898 0.82 0.442 1.15 0.440 1.03 0.674 
BMI visit 1 0.99 0.980 0.92 0.602 0.85 0.358 1.04 0.566 1.07 0.236 1.03 0.810 1.06 0.670 1.08 0.284 
BMI visit 2 1.01 0.766 1.00 0.932 1.01 0.854 1.02 0.752 1.07 0.390 0.83 0.456 1.03 0.814 1.13 0.166 
BMI at age 18 1.05 0.302 1.03 0.692 1.16 0.296 1.05 0.380 1.04 0.386 1.05 0.694 1.15 0.328 1.02 0.684 
BMI at max 0.97 0.752 0.96 0.792 1.19 0.248 0.96 0.716 1.00 1.030 0.89 0.586 1.18 0.294 1.00 1.072 
hip visit 1 0.98 0.854 0.90 0.444 0.88 0.492 1.01 0.780 1.05 0.410 1.09 0.590 0.96 0.848 1.06 0.390 
hip visit 2 1.05 0.398 1.01 0.878 1.16 0.306 1.05 0.500 1.09 0.298 0.83 0.458 1.22 0.324 1.11 0.218 
PBF visit 1 1.01 0.706 0.91 0.468 0.90 0.586 1.06 0.354 1.10 0.132 0.99 1.014 1.13 0.432 1.10 0.152 
PBF visit 2 1.09 0.170 1.00 1.000 0.82 0.354 1.16 0.078 1.12 0.142 0.92 0.782 0.98 1.010 1.18 0.056 
PC2 visit 1 1.12 0.044 1.06 0.596 1.08 0.510 1.14 0.060 1.11 0.090 1.09 0.588 1.05 0.722 1.11 0.120 
PC2 visit 2 1.02 0.668 1.05 0.706 1.35 0.064 0.97 0.812 1.03 0.738 0.69 0.086 1.65 0.020 1.01 0.902 
PC3 visit 1 0.98 0.872 0.92 0.568 0.83 0.264 1.00 0.840 0.93 0.232 0.89 0.574 0.87 0.426 0.95 0.612 
PC3 visit 2 0.99 1.000 1.05 0.724 0.84 0.394 1.01 0.834 0.98 0.886 0.61 0.022 1.08 0.650 1.05 0.534 
waist visit 1 0.96 0.682 0.73 0.008 0.98 0.980 1.02 0.714 1.02 0.654 0.88 0.530 1.12 0.454 1.03 0.664 
waist visit 2 1.02 0.668 1.01 0.878 1.10 0.494 1.02 0.746 1.05 0.454 0.91 0.734 1.06 0.698 1.06 0.480 
WHR females visit 1 0.95 0.550 0.90 0.544 0.94 0.732 0.95 0.650 0.96 0.686 1.10 0.624 1.40 0.070 0.89 0.156 
WHR females visit 2 0.93 0.416 0.78 0.086 1.06 0.692 0.96 0.720 0.84 0.034 0.58 0.014 0.68 0.094 0.95 0.656 
WHR adj BMI females visit 1 1.00 1.000 1.01 0.848 0.91 0.620 1.00 0.852 0.99 0.940 1.33 0.160 1.32 0.096 0.89 0.184 
WHR adj BMI females visit 2 1.00 0.908 0.82 0.168 1.06 0.696 1.04 0.660 0.90 0.232 0.73 0.172 0.78 0.270 0.98 0.928 
WHR males visit 1 1.03 0.690 1.25 0.172 1.26 0.208 0.96 0.690 1.01 0.900 1.39 0.254 1.70 0.110 0.86 0.290 
WHR males visit 2 1.10 0.204 1.28 0.112 0.89 0.572 1.08 0.338 1.01 0.876 0.99 1.000 1.09 0.664 0.99 0.998 
WHR adj BMI males visit 1 0.98 0.890 1.18 0.278 0.87 0.494 0.95 0.720 0.94 0.540 0.82 0.456 1.18 0.482 0.95 0.746 
WHR adj BMI males visit 2 1.00 0.912 1.10 0.568 0.94 0.856 0.99 0.954 0.92 0.468 0.80 0.510 1.01 0.948 0.93 0.630 
WHR visit 1 0.98 0.956 0.77 0.036 0.94 0.826 1.04 0.666 0.96 0.706 0.81 0.324 1.04 0.818 0.98 0.916 
WHR visit 2 1.05 0.396 0.90 0.452 0.98 0.936 1.11 0.224 0.98 0.894 0.70 0.090 0.92 0.724 1.06 0.460 
WHR adj BMI visit 1 1.06 0.236 0.92 0.610 0.79 0.216 1.12 0.212 1.02 0.702 1.07 0.702 1.11 0.618 1.01 0.810 
WHR adj BMI visit 2 1.09 0.214 0.90 0.440 0.93 0.738 1.15 0.090 0.96 0.626 0.72 0.124 0.88 0.574 1.02 0.772 
 Table 22. Systematic enrichment of monogenic adiposity genes. 
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To test for association of rare functional variants in these genes, SKAT-O 
association tests were run on each trait combining all genes each gene set. Across all 
obesity traits, three masks, and four gene sets, no test was significant after correcting for 
multiple testing within trait. Conservatively treating each test as independent, Bonferroni 
correction provides a significance threshold of 0.004 within each trait. The strongest 
associations are shown in Table 23. Protein truncating variants and rare protein altering 
variants predicted damaging by metaLR in syndromic obesity genes are suggestively 
associated with PC3 at visit 2 (p = 0.00535), which captures central versus peripheral 
adiposity. Protein truncating and rare protein altering variants are suggestively 
associated with waist circumference at visit 2 (p = 0.00615).  
trait list mask p-value cMAF 
PC3 visit 2 syndromic LR 0.00535 0.28649 
waist visit 2 lipodystrophy NS 0.00615 0.21538 
Table 23. Global tests of rare variant association. Abbreviations: cMAF: cumulative 
minor allele frequency 
DISCUSSION 
Monogenic adiposity genes, by definition are known to have a large effect 
change when altered. Here we have presented some suggestive evidence that variants in 
MC3R, MCHR1, BB2, and VPS13B may impact central adiposity, as reflected in the 
composite measure PC2 at visit 1. There is also systematic inflation of association with 
PC2 at visit 1 for all monogenic adiposity genes across all variation from the genome-
wide imputed and PC2 at visit 2 for lipodystrophy genes from the exome sequencing 
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data. This supports the notion that a subset of variants in monogenic obesity genes also 
plays a role in common obesity.  
Systematic deflation of variants in these gene sets may be reflective of these 
analyses being limited to type 2 diabetes controls, and individuals meeting diagnostic 
criteria for diabetes for the first time at the current visit. Monogenic obesity patients are 
at high risk for developing diabetes, and many forms of lipodystrophy feature disrupted 
insulin signaling, resulting in exclusion bias that would prevent us from detecting an 
association with these genes. 
The amount of variation seen in these genes shown in Table 21, includes 
individuals with type 2 diabetes along with the controls and newly diagnosed diabetics 
used for analyses. By repeating analyses in type 2 diabetes patients, we may be able to 
detect an effect in these monogenic genes; however, this comes with the added 
uncertainty of the impact of diabetes treatments on each individual’s adiposity. 
Monogenic adiposity genes provide attractive therapeutic targets for both the rare 
cases where the gene is disrupted as well as for common obesity. Leptin injections are 
very effective for the handful of individuals with congenital leptin deficiency(38). 
Recently, the leptin injects have regained popularity, as their use in individuals with 
leptin deficiency due to lipodystrophy has recently been approved by the FDA(229, 
230). Unfortunately it is not effective for common obesity, in which a majority of people 
is leptin resistant. More recently, MCHR1 antagonists have been introduced as potential 
obesity therapeutic agents(231-234). However none of these have reached the stage of 
clinical trials yet. 
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Monogenic adiposity genes are easier to identify than common adiposity genes. 
The biological pathways disrupted by monogenic obesity genes are sometimes disrupted 
in common obesity to a lesser extent, nonetheless making the pathways plausible 
therapeutic targets for common obesity.  
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Chapter 7: Conclusions 
In this dissertation we have investigated various measures of adiposity that may 
better capture genetic aspects of obesity and the role of common and rare genetic 
variation related to these measures utilizing the resources developed Starr County, Texas 
Mexican Americans. In this chapter we synthesize the results and highlight findings 
regarding potentially new variation that may be involved in adiposity both through lipid 
metabolism and neurological development and signaling pathways, which all play a role 
in hunger and satiety.  
The two multivariate methods, principal components analyses and meta-analysis 
of multiple traits, have different genetic results. The first, principal components analysis, 
used the raw obesity measures as input. These components were then adjusted for age 
and sex. Alternatively, the age and sex adjusted residuals could have been used. 
However, this would not capture a person’s objectively measured shape. Principal 
components analysis showed that BMI, the most widely used measure of obesity, 
captures 82% of the variation in the array of anthropometric traits used here. This 
indicates most variation in adiposity has been well captured in studies of adiposity, 
despite the small portion of heritability explained. Two additional composite measures 
of adiposity, PC2 and PC3 were shown to capture different aspects of adiposity, 
although they capture a much smaller proportion of the variation in obesity 
measurements. PC2 appears to capture the amount of adipose tissue and if it is located 
above or below the waist. It is through this measure that we replicate a prior suggestive 
association with subcutaneous adipose tissue to visceral adipose ratio. The later requires 
medical imaging to obtain making it cost prohibitive on a large scale. The use of a 
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principal components strategy based on more readily obtainable measures should 
facilitate implementing such studies in larger samples. PC3 captured peripheral versus 
central adiposity, which is quite similar to the ratio of arm circumference to waist 
circumference. PC3 identified multiple functionally plausible associations including rare 
variants in ACSL1, a gene involved triglyceride synthesis and beta oxidation; DSCAM 
which is expressed in the brain and pituitary gland, and GCM2, a key switch in neuronal 
development. The identification of these candidates suggests that by adding arm to waist 
ratio to the set of routinely to anthropometric measures has the potential for identifying 
more genes effecting fat distribution. This highlights our argument that more refined 
biologically relevant measures should enhance our ability to implicate genes. 
The second multivariate approach was to meta-analyze the results across the 
traits at two time points while adjusting for the correlation between the test statistics. 
Essentially, this combines the evidence of a variant’s or gene’s involvement for each 
trait, but this cannot be done without considering that the traits, and therefore results, are 
correlated with each other. This was done using the method CPASSOC to adjust for the 
correlation between test-statistics in the meta-analysis(176). This approach also 
identified biologically plausible associations, including a variant near the gene encoding 
a key skeletal muscle protein, myosin heavy chain 13, and DLG4, which is oriented head 
to head with ACADVL. DLG4 and ACADVL are both functionally interesting, as DLG4 
is involved in synaptic junction maintenance and ACADVL is involved in beta-oxidation 
of fatty acids. While this approach did have some success, it is intended to detect 
plieotropy. The traits studied here are all measures of the same phenotype, distribution of 
body fat. However each measure excels in capturing a different dimension of adiposity. 
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Despite having different strengths, the measures are correlated with each other. The 
correction for this correlation decreases the weight of each trait, hindering the power of 
this approach. It does have the potential to be very powerful, particularly when 
considering true pleiotropic effects with different metabolic outcomes.  
With the same sets of obesity traits measured at two different time points there 
are multiple approaches for dealing with them. Here I analyzed the measured as two 
different outcomes. Another approach would be to look at how individuals changed over 
time. For example one could analyze the average annual change in each measure; 
however, this would limit samples size to the smaller subset that did not have diabetes at 
the second visit. This approach will provide a different set of association results, and 
may identify additional obesity loci. Furthermore initially one may think highly 
correlated results would be expected. This is not what we observe, with good reason. 
Because we have excluded individuals previously diagnosed with diabetes from these 
analyses, the subset of individuals analyzed from the second visit is a non-random 
subset. This introduces an exclusion bias by removing the subset that developed diabetes 
over a short time span, which had a higher average BMI at the first visit. To better 
understand the impact of exclusion bias as well as the adiposity profile of those most at 
risk for developing diabetes exploratory analyses such as looking at the correlation 
between genetic associations at visit 1 and visit 2 using only the subset of people that did 
not develop diabetes. A useful multivariate approach to understand adiposity profiles in 
those most likely to develop diabetes would be to make a composite measure based on 
linear discriminant analysis aimed at separating those that develop diabetes between 
visits from those that do not. This may help identify adiposity profiles at increased risk 
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for developing diabetes allowing for additional intervention aimed at preventing the 
development of diabetes. The resulting linear combinations of adiposity traits could also 
be analyzed for genetic associations. 
Through this work a number of genes that may be involved in body fat 
distribution have been identified; however, with most only being suggestively associated 
additional work is needed to confirm these associations. First, variants that were imputed 
at a lower quality must undergo validation genotyping. Some variants, such those In 
GABRA6 and GABRB2 are biologically compelling; particularly in light of recent rodent 
models showing that GABA producing neurons are involved in compulsive sucrose 
seeking(225, 226).  
To bolster statistical support for the involvement of these novel genes in obesity, 
replication in an independent data set is ideal. There are several options here, depending 
on the phenotype the association was observed with. BMI and WHR are readily 
available. With the 43 published genome wide association studies, some of these 
variants have been interrogated before. While these associations have not been seen 
before, looking at other studies’ sub-significant results is one source of replication. 
Many of the variants of interest, particularly rare coding variants, will not have been 
tested because smaller arrays and imputation reference panels were used. Studies using 
larger data sets are still underway; in fact these data have been contributed to multiple 
consortia looking at these traits. BMI and WHR for the genome-wide chip data imputed 
to 1000 Genomes are part of the HISLA Consortium, which is meta-analyzing BMI, and 
WHR across many Hispanic studies. The exome sequencing data set is a portion of the 
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T2D-GENES consortium, which plans to analyze both BMI and WHR across 13,000 
samples.  
In addition to these consortia, additional individuals form Starr County are 
currently being genotyped: 2000 samples are undergoing exome sequencing, 900 
samples are being genotyped on a chip custom designed by the PAGE consortium which 
is enriched for low frequency coding variation previously seen in minority samples. 
These would be ethnically matched to the current data, and would have the same set of 
anthropometric measures available. 
The clearest limitation of this work is the lack of power. With a limited sample 
size ranging from 825 all the way down to 89 in male specific analyses at the second 
visit, these analyses are underpowered, particularly for rare and low frequency variants. 
With the largest sample size here we only have 80% power to detect an effect size of at 
least 0.7 standard deviations in a variant with a 1% minor allele frequency. This is a 
much larger effect size than has been detected thus far. There are multiple options for 
overcoming the lack of power when it comes to low frequency variants.  
The most obvious option is increasing sample size. One consortium, GIANT is 
aiming to have more than 1 million individuals in their analyses of data sets imputed out 
to 1000 Genomes. In the GIANTexomes consortium, almost 500,000 individuals with 
exome chip data are being meta-analyzed, with additional studies potentially 
contributing to replication analyses. The exome chip captures primarily rare and low 
frequency coding variants and has a much-reduced per-sample cost in comparison to 
sequencing. However, increasing power by increasing sample size has its limitations. 
BMI and WHR are “extra traits” collected by most groups studying the genetic outcomes 
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of other phenotypes and diseases; however, the expanded set of adiposity traits used here 
are often not measured. With many contributing studies there are sources of bias and 
error that can be difficult to detect and account for. Some of the outcomes data were 
ascertained for may alter body composition, as type 2 diabetes and subsequent treatment 
does. Additionally ascertainment schemes can introduce bias for add-on traits. 
Another means to increase power is to bias sample collection to include carriers 
of rare variants of interest. For years this approach has been implemented by genotyping 
individuals with the most extreme outcomes. With sequencing data in hand, we can also 
enrich for a particular variant of interest by recruiting family members into the study. In 
the case of family members different analytical approaches, such as linkage, that 
leverage relatedness rather than adjust for relatedness are necessary.  
While we know that a majority of the estimated heritability is unaccounted for 
there are many association signals that are statistically convincing. However, there has 
been a lack of functional follow up work to understand the biological role of these 
variants and genes. Functional follow up is an expensive and time-consuming prospect. 
It is our responsibility as quantitative geneticists to present molecular biologists with a 
compelling case that these genes and variants are worth their investment. To do this, 
high throughput datasets, such as the GTEx project which has gene expression data for 
many tissues as well as genotypes, can be used to show a gene is expressed in a relevant 
tissue and if a variant has an impact on gene expression(209). For coding variants, the 
functional prediction can be taken a step beyond in the in silico prediction tools used to 
annotate variants. Existing 3D models of the protein can be utilized to view the location 
and predict the impact of an amino acid change on protein function. Additional data 
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types, such as methylation data, but can also be used to make the case that a gene and 
variant are involved in obesity. Once we have made this case for a gene, molecular 
biologists can then study the impact of a particular variant and assess the gene’s 
biological role. The long-term goal of understanding the underlying biology is to identify 
therapeutic targets. Diet and exercise are only effective for long-term weight control in a 
subset of people. Because the obesity epidemic shows no signs of slowing down, it is 




Appendix Figure 1 Scatter plot matrix of anthropometric measures and resulting 
PCs for visit 1. The bottom half shows the scatter plot for each pair of traits, with PC2 
in the bottom row. The upper half shows the Pearson correlation coefficient for the two 
measures. Histograms of the traits are displayed in the middle. Points are color coded by 
sex and obesity status. Obese males are dark blue; non-obese males are light blue; obese 
females are red, non-obese females are pink  
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Appendix Figure 2 Scatter plot matrix of PCs and anthropometric measures for 
visit 2. The bottom half shows the scatter plot for each pair of traits, with PC2 in the 
bottom row. The upper half shows the Pearson correlation coefficient for the two 
measures. Histograms of the traits are displayed in the middle. Points are color coded by 
sex and obesity status. Obese males are dark blue; non-obese males are light blue; obese 
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